|
feed.0.url
https://www.benzinga.com/markets/cannabis/24/09/40736485/psychedelic-drugs-market-set-to-grow-by-1-37b-by-2028-driven-by-mental-health-disorders-and-ai-i
|
items
50
|
relevance_score_definition
0 < x <= 1, with a higher score indicating higher relevance.
|
feed.0.authors.0
Juan SpÃ­nelli
|
feed.0.title
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration - ATAI Life Sciences  ( NASDAQ:ATAI ) , AbbVie  ( NYSE:ABBV ) 
|
feed.0.summary
The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio.
|
feed.0.banner_image
https://cdn.benzinga.com/files/images/story/2024/09/05/3.png?width=1200&height=800&fit=crop
|
feed.0.source
Benzinga
|
feed.0.category_within_source
News
|
feed.0.source_domain
www.benzinga.com
|
feed.0.topics.0.topic
Life Sciences
|
feed.0.topics.0.relevance_score
0.5
|
feed.0.topics.1.topic
Technology
|
feed.0.topics.1.relevance_score
0.5
|
feed.0.topics.2.topic
Financial Markets
|
feed.0.topics.2.relevance_score
0.108179
|
feed.0.overall_sentiment_score
0.176509
|
feed.0.overall_sentiment_label
Somewhat-Bullish
|
feed.0.ticker_sentiment.0.ticker
CMPS
|
feed.0.ticker_sentiment.0.relevance_score
0.077094
|
feed.0.ticker_sentiment.0.ticker_sentiment_score
0.137835
|
feed.0.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.0.ticker_sentiment.1.ticker
ABBV
|
feed.0.ticker_sentiment.1.relevance_score
0.15347
|
feed.0.ticker_sentiment.1.ticker_sentiment_score
0.175227
|
feed.0.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.0.ticker_sentiment.2.ticker
MNMD
|
feed.0.ticker_sentiment.2.relevance_score
0.15347
|
feed.0.ticker_sentiment.2.ticker_sentiment_score
0.175227
|
feed.0.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.0.ticker_sentiment.3.ticker
PFE
|
feed.0.ticker_sentiment.3.relevance_score
0.15347
|
feed.0.ticker_sentiment.3.ticker_sentiment_score
0.175227
|
feed.0.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.0.ticker_sentiment.4.ticker
JNJ
|
feed.0.ticker_sentiment.4.relevance_score
0.15347
|
feed.0.ticker_sentiment.4.ticker_sentiment_score
0.175227
|
feed.0.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.1.title
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.1.url
https://www.benzinga.com/markets/cannabis/24/08/40318640/psychedelics-company-mindmed-prices-public-offering-aiming-to-raise-75m
|
feed.1.time_published
20240812T161459
|
feed.1.authors.0
Nina Zdinjak
|
feed.1.summary
A psychedelics-focused biopharmaceutical company Mind Medicine ( MindMed ) MNMD announced Friday the pricing of an underwritten public offering of 9.29 million shares without par value, at a price of $7.00 per share. Through this round, the New York-headquartered company aims to raise $75 million.
|
feed.1.banner_image
https://cdn.benzinga.com/files/images/story/2024/08/12/MindMed-healthcare-setting.jpeg?width=1200&height=800&fit=crop
|
feed.1.source
Benzinga
|
feed.1.category_within_source
Markets
|
feed.1.source_domain
www.benzinga.com
|
feed.1.topics.0.topic
IPO
|
feed.1.topics.0.relevance_score
0.158519
|
feed.1.topics.1.topic
Technology
|
feed.1.topics.1.relevance_score
0.5
|
feed.1.topics.2.topic
Finance
|
feed.1.topics.2.relevance_score
0.5
|
feed.1.overall_sentiment_score
0.192104
|
feed.1.overall_sentiment_label
Somewhat-Bullish
|
feed.1.ticker_sentiment.0.ticker
EVR
|
feed.1.ticker_sentiment.0.relevance_score
0.126119
|
feed.1.ticker_sentiment.0.ticker_sentiment_score
0.082032
|
feed.1.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.1.ticker_sentiment.1.ticker
MNMD
|
feed.1.ticker_sentiment.1.relevance_score
0.249106
|
feed.1.ticker_sentiment.1.ticker_sentiment_score
0.096569
|
feed.1.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.2.title
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.2.url
https://www.benzinga.com/markets/cannabis/24/06/39514845/groundbreaking-fentanyl-vaccine-being-developed-to-prevent-fatal-overdoses-startup-secures-10m
|
feed.2.time_published
20240626T225807
|
feed.2.authors.0
Maureen Meehan
|
feed.2.summary
A promising new startup, Ovax Inc., secured $10 million in funding to advance the development of a groundbreaking vaccine designed to prevent fentanyl-related deaths. The initiative focuses on commercializing academic research aimed at preventing the potent opioid from reaching the brain, ...
|
feed.2.banner_image
https://cdn.benzinga.com/files/images/story/2024/06/26/Fentanyl-Shutterstock.jpeg?width=1200&height=800&fit=crop
|
feed.2.source
Benzinga
|
feed.2.category_within_source
News
|
feed.2.source_domain
www.benzinga.com
|
feed.2.topics.0.topic
IPO
|
feed.2.topics.0.relevance_score
0.158519
|
feed.2.topics.1.topic
Technology
|
feed.2.topics.1.relevance_score
1.0
|
feed.2.overall_sentiment_score
0.129031
|
feed.2.overall_sentiment_label
Neutral
|
feed.2.ticker_sentiment.0.ticker
MNMD
|
feed.2.ticker_sentiment.0.relevance_score
0.152499
|
feed.2.ticker_sentiment.0.ticker_sentiment_score
-0.053722
|
feed.2.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.3.title
Is Mind Medicine MindMed  ( MNMD )  Outperforming Other Medical Stocks This Year?
|
feed.3.url
https://www.zacks.com/stock/news/2288431/is-mind-medicine-mindmed-mnmd-outperforming-other-medical-stocks-this-year
|
feed.3.time_published
20240614T134010
|
feed.3.authors.0
Zacks Equity Research
|
feed.3.summary
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
|
feed.3.banner_image
https://staticx-tuner.zacks.com/images/default_article_images/default216.jpg
|
feed.3.source
Zacks Commentary
|
feed.3.category_within_source
n/a
|
feed.3.source_domain
www.zacks.com
|
feed.3.topics.0.topic
Life Sciences
|
feed.3.topics.0.relevance_score
0.5
|
feed.3.topics.1.topic
Financial Markets
|
feed.3.topics.1.relevance_score
0.161647
|
feed.3.topics.2.topic
Earnings
|
feed.3.topics.2.relevance_score
0.614606
|
feed.3.topics.3.topic
Technology
|
feed.3.topics.3.relevance_score
0.5
|
feed.3.overall_sentiment_score
0.212308
|
feed.3.overall_sentiment_label
Somewhat-Bullish
|
feed.3.ticker_sentiment.0.ticker
MNMD
|
feed.3.ticker_sentiment.0.relevance_score
0.747404
|
feed.3.ticker_sentiment.0.ticker_sentiment_score
0.373248
|
feed.3.ticker_sentiment.0.ticker_sentiment_label
Bullish
|
sentiment_score_definition
x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish
|
feed.3.ticker_sentiment.1.ticker
RMD
|
feed.3.ticker_sentiment.1.relevance_score
0.388879
|
feed.3.ticker_sentiment.1.ticker_sentiment_score
0.191908
|
feed.3.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.4.title
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
|
feed.4.time_published
20240610T122500
|
feed.4.url
https://www.fool.com/investing/2024/06/10/psychedelics-stocks-are-falling-after-a-shocking-v/
|
feed.4.authors.0
Alex Carchidi
|
feed.4.summary
Regulators were not impressed by one company's petition for approval.
|
feed.4.banner_image
https://g.foolcdn.com/editorial/images/780000/investor-looks-angrily-at-laptop.jpg
|
feed.4.source
Motley Fool
|
feed.4.category_within_source
n/a
|
feed.4.source_domain
www.fool.com
|
feed.4.topics.0.topic
Life Sciences
|
feed.4.topics.0.relevance_score
0.5
|
feed.4.topics.1.topic
Technology
|
feed.4.topics.1.relevance_score
0.5
|
feed.4.overall_sentiment_score
0.103578
|
feed.4.overall_sentiment_label
Neutral
|
feed.4.ticker_sentiment.0.ticker
MNMD
|
feed.4.ticker_sentiment.0.relevance_score
0.047559
|
feed.4.ticker_sentiment.0.ticker_sentiment_score
-0.04993
|
feed.4.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.4.ticker_sentiment.1.ticker
CMPS
|
feed.4.ticker_sentiment.1.relevance_score
0.09495
|
feed.4.ticker_sentiment.1.ticker_sentiment_score
-0.014109
|
feed.4.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.5.title
Three Stocks: Mind Medicine, CrowdStrike, and Hewlett Packard
|
feed.5.url
https://moneymorning.com/2024/06/05/three-stocks-mind-medicine-crowdstrike-and-hewlett-packard/
|
feed.5.time_published
20240605T232712
|
feed.5.authors.0
Chris Johnson
|
feed.5.summary
Shares of Mind Medicine ( MNMD ) traded as much as 20% lower today in the wake of an announcement from an FDA advisory committee. The advisory committee issued a negative vote on a psychedelic treatment being developed by Lykos.
|
feed.5.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2018/11/Retina_Headshots_ChrisJohnson.jpg
|
feed.5.source
Money Morning
|
feed.5.category_within_source
RSS
|
feed.5.source_domain
moneymorning.com
|
feed.5.topics.0.topic
Retail & Wholesale
|
feed.5.topics.0.relevance_score
0.5
|
feed.5.topics.1.topic
Financial Markets
|
feed.5.topics.1.relevance_score
0.316726
|
feed.5.topics.2.topic
Earnings
|
feed.5.topics.2.relevance_score
0.999953
|
feed.5.topics.3.topic
Technology
|
feed.5.topics.3.relevance_score
0.5
|
feed.5.overall_sentiment_score
0.161596
|
feed.5.overall_sentiment_label
Somewhat-Bullish
|
feed.5.ticker_sentiment.0.ticker
ADBE
|
feed.5.ticker_sentiment.0.relevance_score
0.121959
|
feed.5.ticker_sentiment.0.ticker_sentiment_score
0.01853
|
feed.5.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.5.ticker_sentiment.1.ticker
HPQ
|
feed.5.ticker_sentiment.1.relevance_score
0.121959
|
feed.5.ticker_sentiment.1.ticker_sentiment_score
0.132321
|
feed.5.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.5.ticker_sentiment.2.ticker
CRWD
|
feed.5.ticker_sentiment.2.relevance_score
0.298749
|
feed.5.ticker_sentiment.2.ticker_sentiment_score
0.229532
|
feed.5.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.5.ticker_sentiment.3.ticker
HPE
|
feed.5.ticker_sentiment.3.relevance_score
0.121959
|
feed.5.ticker_sentiment.3.ticker_sentiment_score
0.177257
|
feed.5.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.5.ticker_sentiment.4.relevance_score
0.121959
|
feed.5.ticker_sentiment.4.ticker
MNMD
|
feed.5.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.5.ticker_sentiment.4.ticker_sentiment_score
-0.105693
|
feed.5.ticker_sentiment.5.ticker
NOW
|
feed.5.ticker_sentiment.5.relevance_score
0.061159
|
feed.5.ticker_sentiment.5.ticker_sentiment_score
0.016015
|
feed.5.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.6.title
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment - ATAI Life Sciences  ( NASDAQ:ATAI ) , Cybin  ( AMEX:CYBN ) 
|
feed.6.url
https://www.benzinga.com/markets/psychedelics/24/06/39192640/psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment
|
feed.6.time_published
20240605T192650
|
feed.6.authors.0
Aaron Bry
|
feed.6.summary
A panel of advisors to the Food and Drug Administration ( FDA ) rejected MDMA as a treatment for post-traumatic stress disorder ( PTSD ) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients.
|
feed.6.banner_image
https://cdn.benzinga.com/files/images/story/2024/06/05/US-Psychedelic-Law-Acontent-creator-and-.jpeg?width=1200&height=800&fit=crop
|
feed.6.source
Benzinga
|
feed.6.source_domain
www.benzinga.com
|
feed.6.category_within_source
General
|
feed.6.topics.0.topic
Technology
|
feed.6.topics.0.relevance_score
1.0
|
feed.6.topics.1.topic
Financial Markets
|
feed.6.topics.1.relevance_score
0.650727
|
feed.6.overall_sentiment_score
-0.057775
|
feed.6.overall_sentiment_label
Neutral
|
feed.6.ticker_sentiment.0.ticker
MNMD
|
feed.6.ticker_sentiment.0.relevance_score
0.204072
|
feed.6.ticker_sentiment.0.ticker_sentiment_score
-0.087176
|
feed.6.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.7.title
Psychedelic Stocks Tank After FDA Advisors Shoot Down MDMA Therapy For PTSD
|
feed.7.url
https://www.forbes.com/sites/roberthart/2024/06/05/psychedelic-stocks-tank-after-fda-advisors-shoot-down-mdma-therapy-for-ptsd/
|
feed.7.time_published
20240605T140420
|
feed.7.authors.0
Robert Hart
|
feed.7.summary
Shares for companies focused on psychedelic medicines plummeted during premarket trading on Wednesday after independent experts advised the Food and Drug Administration against approving psychedelic and stimulant drug MDMA, commonly known as ecstacy or molly, for post-traumatic stress disorder, ...
|
feed.7.banner_image
https://imageio.forbes.com/specials-images/imageserve/666069a06d0c95dd2bca7c19/0x0.jpg?format=jpg&crop=1326,745,x0,y68,safe&height=900&width=1600&fit=bounds
|
feed.7.source
Forbes
|
feed.7.category_within_source
n/a
|
feed.7.source_domain
www.forbes.com
|
feed.7.topics.0.topic
Life Sciences
|
feed.7.topics.0.relevance_score
0.5
|
feed.7.topics.1.topic
Technology
|
feed.0.time_published
20240905T165346
|
feed.7.topics.1.relevance_score
0.5
|
feed.7.topics.2.topic
Financial Markets
|
feed.7.topics.2.relevance_score
0.214378
|
feed.7.overall_sentiment_score
0.097227
|
feed.7.overall_sentiment_label
Neutral
|
feed.7.ticker_sentiment.0.ticker
CMPS
|
feed.7.ticker_sentiment.0.relevance_score
0.074692
|
feed.7.ticker_sentiment.0.ticker_sentiment_score
0.073578
|
feed.7.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.7.ticker_sentiment.1.ticker
MNMD
|
feed.7.ticker_sentiment.1.ticker_sentiment_score
0.073578
|
feed.7.ticker_sentiment.1.relevance_score
0.074692
|
feed.7.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.7.ticker_sentiment.2.ticker
RLMD
|
feed.7.ticker_sentiment.2.relevance_score
0.074692
|
feed.7.ticker_sentiment.2.ticker_sentiment_score
0.073578
|
feed.7.ticker_sentiment.3.relevance_score
0.074692
|
feed.7.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.7.ticker_sentiment.3.ticker
SEEL
|
feed.7.ticker_sentiment.3.ticker_sentiment_score
0.073578
|
feed.7.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.8.title
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - DouYu Intl Hldgs  ( NASDAQ:DOYU ) 
|
feed.8.url
https://www.benzinga.com/news/24/06/39181909/douyu-international-posts-q1-results-joins-annexon-dollar-tree-and-other-big-stocks-moving-lower-in
|
feed.8.time_published
20240605T120739
|
feed.8.authors.0
Avi Kapoor
|
feed.8.summary
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Wednesday. Shares of DouYu International Holdings Limited DOYU fell in today's pre-market trading following first-quarter results.
|
feed.8.banner_image
https://cdn.benzinga.com/files/images/story/2024/06/05/Image46.jpeg?width=1200&height=800&fit=crop
|
feed.8.source
Benzinga
|
feed.8.category_within_source
Trading
|
feed.8.source_domain
www.benzinga.com
|
feed.8.topics.0.relevance_score
0.333333
|
feed.8.topics.0.topic
Life Sciences
|
feed.8.topics.1.relevance_score
0.158519
|
feed.8.topics.2.relevance_score
0.333333
|
feed.8.topics.1.topic
IPO
|
feed.8.topics.2.topic
Retail & Wholesale
|
feed.8.topics.3.topic
Financial Markets
|
feed.8.topics.3.relevance_score
0.99977
|
feed.8.topics.4.topic
Earnings
|
feed.8.topics.4.relevance_score
0.714479
|
feed.8.topics.5.topic
Technology
|
feed.8.overall_sentiment_label
Neutral
|
feed.8.topics.5.relevance_score
0.333333
|
feed.8.overall_sentiment_score
-0.061594
|
feed.8.ticker_sentiment.0.ticker
CMPS
|
feed.8.ticker_sentiment.0.relevance_score
0.268294
|
feed.8.ticker_sentiment.0.ticker_sentiment_score
0.372984
|
feed.8.ticker_sentiment.0.ticker_sentiment_label
Bullish
|
feed.8.ticker_sentiment.1.ticker
DLTR
|
feed.8.ticker_sentiment.1.relevance_score
0.268294
|
feed.8.ticker_sentiment.1.ticker_sentiment_score
-0.051105
|
feed.8.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.8.ticker_sentiment.2.ticker
AMC
|
feed.8.ticker_sentiment.2.relevance_score
0.268294
|
feed.8.ticker_sentiment.2.ticker_sentiment_score
-0.130232
|
feed.8.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.8.ticker_sentiment.3.ticker
DOYU
|
feed.8.ticker_sentiment.3.relevance_score
0.507107
|
feed.8.ticker_sentiment.3.ticker_sentiment_score
-0.34221
|
feed.8.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bearish
|
feed.8.ticker_sentiment.4.ticker
MDGL
|
feed.8.ticker_sentiment.4.relevance_score
0.268294
|
feed.8.ticker_sentiment.4.ticker_sentiment_score
-0.502622
|
feed.8.ticker_sentiment.4.ticker_sentiment_label
Bearish
|
feed.8.ticker_sentiment.5.ticker
ANNX
|
feed.8.ticker_sentiment.5.relevance_score
0.268294
|
feed.8.ticker_sentiment.5.ticker_sentiment_score
-0.068357
|
feed.8.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.8.ticker_sentiment.6.ticker
IAS
|
feed.8.ticker_sentiment.6.relevance_score
0.268294
|
feed.8.ticker_sentiment.6.ticker_sentiment_score
-0.130232
|
feed.8.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.8.ticker_sentiment.7.ticker
MNMD
|
feed.8.ticker_sentiment.7.relevance_score
0.268294
|
feed.8.ticker_sentiment.7.ticker_sentiment_score
-0.333474
|
feed.8.ticker_sentiment.7.ticker_sentiment_label
Somewhat-Bearish
|
feed.9.title
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Stitch Fix  ( NASDAQ:SFIX ) 
|
feed.9.url
https://www.benzinga.com/news/24/06/39178410/why-stitch-fix-shares-are-trading-higher-by-18-here-are-20-stocks-moving-premarket
|
feed.9.time_published
20240605T092725
|
feed.9.authors.0
Avi Kapoor
|
feed.9.summary
Shares of Stitch Fix, Inc. SFIX rose sharply in today's pre-market trading following better-than-expected third-quarter financial results. Stitch Fix reported quarterly losses of 18 cents per share which beat the analyst consensus estimate of losses of 24 cents by 25%.
|
feed.9.banner_image
https://cdn.benzinga.com/files/images/story/2024/06/05/xrdDAFlJhBnMXo2-j1217490490970756473-t23.jpeg?width=1200&height=800&fit=crop
|
feed.9.category_within_source
Markets
|
feed.9.source_domain
www.benzinga.com
|
feed.9.source
Benzinga
|
feed.9.topics.0.topic
Life Sciences
|
feed.9.topics.0.relevance_score
0.333333
|
feed.9.topics.1.topic
IPO
|
feed.9.topics.1.relevance_score
0.310843
|
feed.9.topics.3.topic
Financial Markets
|
feed.9.topics.2.topic
Retail & Wholesale
|
feed.9.topics.2.relevance_score
0.333333
|
feed.9.topics.3.relevance_score
1.0
|
feed.9.topics.4.topic
Earnings
|
feed.9.topics.5.relevance_score
0.333333
|
feed.9.overall_sentiment_score
0.100275
|
feed.9.overall_sentiment_label
Neutral
|
feed.9.ticker_sentiment.0.ticker
NDRA
|
feed.9.topics.4.relevance_score
0.158519
|
feed.9.topics.5.topic
Technology
|
feed.9.ticker_sentiment.0.relevance_score
0.20997
|
feed.9.ticker_sentiment.0.ticker_sentiment_score
0.336086
|
feed.9.ticker_sentiment.1.ticker_sentiment_score
0.048765
|
feed.9.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.9.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.1.ticker
MLGO
|
feed.9.ticker_sentiment.1.relevance_score
0.140896
|
feed.9.ticker_sentiment.2.ticker
MGRX
|
feed.9.ticker_sentiment.2.relevance_score
0.20997
|
feed.9.ticker_sentiment.2.ticker_sentiment_score
-0.074787
|
feed.9.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.3.ticker
SFIX
|
feed.9.ticker_sentiment.3.relevance_score
0.277433
|
feed.9.ticker_sentiment.3.ticker_sentiment_score
0.113761
|
feed.9.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.4.ticker
WKME
|
feed.9.ticker_sentiment.4.relevance_score
0.20997
|
feed.9.ticker_sentiment.4.ticker_sentiment_score
0.236177
|
feed.9.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.9.ticker_sentiment.5.ticker
VSTE
|
feed.9.ticker_sentiment.5.relevance_score
0.140896
|
feed.9.ticker_sentiment.5.ticker_sentiment_score
-0.167745
|
feed.9.ticker_sentiment.5.ticker_sentiment_label
Somewhat-Bearish
|
feed.9.ticker_sentiment.6.ticker
HPQ
|
feed.9.ticker_sentiment.6.relevance_score
0.070725
|
feed.9.ticker_sentiment.6.ticker_sentiment_score
0.281431
|
feed.9.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bullish
|
feed.9.ticker_sentiment.7.ticker
ANNX
|
feed.9.ticker_sentiment.7.relevance_score
0.140896
|
feed.9.ticker_sentiment.7.ticker_sentiment_score
-0.042634
|
feed.9.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.8.ticker
ASNS
|
feed.9.ticker_sentiment.8.relevance_score
0.140896
|
feed.9.ticker_sentiment.8.ticker_sentiment_score
0.0
|
feed.9.ticker_sentiment.8.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.9.ticker
SOBR
|
feed.9.ticker_sentiment.9.relevance_score
0.140896
|
feed.9.ticker_sentiment.9.ticker_sentiment_score
-0.058051
|
feed.9.ticker_sentiment.9.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.10.ticker
CCM
|
feed.9.ticker_sentiment.10.relevance_score
0.140896
|
feed.9.ticker_sentiment.10.ticker_sentiment_score
-0.137215
|
feed.9.ticker_sentiment.10.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.11.ticker
MFI
|
feed.9.ticker_sentiment.11.relevance_score
0.140896
|
feed.9.ticker_sentiment.11.ticker_sentiment_score
0.052319
|
feed.9.ticker_sentiment.11.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.12.ticker
THMO
|
feed.9.ticker_sentiment.12.relevance_score
0.140896
|
feed.9.ticker_sentiment.12.ticker_sentiment_score
0.127617
|
feed.9.ticker_sentiment.12.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.13.ticker_sentiment_score
-0.081764
|
feed.9.ticker_sentiment.13.relevance_score
0.140896
|
feed.9.ticker_sentiment.13.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.14.ticker
JYD
|
feed.9.ticker_sentiment.14.relevance_score
0.140896
|
feed.9.ticker_sentiment.13.ticker
CMPS
|
feed.9.ticker_sentiment.14.ticker_sentiment_score
-0.065681
|
feed.9.ticker_sentiment.14.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.15.ticker
BGXX
|
feed.9.ticker_sentiment.15.relevance_score
0.140896
|
feed.9.ticker_sentiment.15.ticker_sentiment_score
0.322585
|
feed.9.ticker_sentiment.15.ticker_sentiment_label
Somewhat-Bullish
|
feed.9.ticker_sentiment.16.ticker
FRES
|
feed.9.ticker_sentiment.16.ticker_sentiment_score
0.135006
|
feed.9.ticker_sentiment.16.ticker_sentiment_label
Neutral
|
feed.9.ticker_sentiment.17.ticker
HPE
|
feed.9.ticker_sentiment.17.ticker_sentiment_label
Somewhat-Bullish
|
feed.9.ticker_sentiment.18.ticker
MNMD
|
feed.9.ticker_sentiment.18.relevance_score
0.140896
|
feed.9.ticker_sentiment.18.ticker_sentiment_score
-0.213688
|
feed.9.ticker_sentiment.18.ticker_sentiment_label
Somewhat-Bearish
|
feed.9.ticker_sentiment.16.relevance_score
0.140896
|
feed.9.ticker_sentiment.17.relevance_score
0.140896
|
feed.9.ticker_sentiment.19.relevance_score
0.140896
|
feed.9.ticker_sentiment.17.ticker_sentiment_score
0.341981
|
feed.9.ticker_sentiment.19.ticker
GDHG
|
feed.9.ticker_sentiment.19.ticker_sentiment_score
-0.053855
|
feed.9.ticker_sentiment.19.ticker_sentiment_label
Neutral
|
feed.10.title
Optimi Health Awarded Drug Establishment Licence From Health Canada
|
feed.10.authors.0
Optimi Health Corp.
|
feed.10.url
https://www.newswire.ca/news-releases/optimi-health-awarded-drug-establishment-licence-from-health-canada-841570037.html
|
feed.10.time_published
20240603T153600
|
feed.10.summary
VANCOUVER, BC, June 3, 2024 /CNW/ - Optimi Health Corp. ( CSE: OPTI ) ( OTCQX: OPTHF ) ( FRA: 8BN ) ( "Optimi" or the "Company" ) , a leading Health Canada-licensed psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to ...
|
feed.10.banner_image
https://mma.prnewswire.com/media/2428469/Optimi_Health_Corp__Optimi_Health_Awarded_Drug_Establishment_Lic.jpg?p=facebook
|
feed.10.source
Canada Newswire
|
feed.10.category_within_source
n/a
|
feed.10.source_domain
www.newswire.ca
|
feed.10.topics.0.topic
Technology
|
feed.10.topics.0.relevance_score
1.0
|
feed.10.topics.1.topic
Financial Markets
|
feed.10.topics.1.relevance_score
0.360215
|
feed.10.overall_sentiment_score
0.236797
|
feed.10.overall_sentiment_label
Somewhat-Bullish
|
feed.10.ticker_sentiment.0.ticker
MNMD
|
feed.10.ticker_sentiment.0.relevance_score
0.049322
|
feed.10.ticker_sentiment.0.ticker_sentiment_score
0.079563
|
feed.10.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.11.title
Three Stocks: American Airlines, Mind Medicine, and GameStop
|
feed.11.url
https://moneymorning.com/2024/05/29/three-stocks-american-airlines-mind-medicine-and-gamestop/
|
feed.11.time_published
20240530T011643
|
feed.11.authors.0
Chris Johnson
|
feed.11.summary
American Airlines ( AAL ) shares closed the day 13% lower after the company adjusted their upcoming quarterly earnings expectations lower. The stock was the worst performer of all the S&P 500 stocks today.
|
feed.11.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2024/05/aal.png
|
feed.11.source
Money Morning
|
feed.11.category_within_source
RSS
|
feed.11.source_domain
moneymorning.com
|
feed.11.topics.0.topic
Retail & Wholesale
|
feed.11.topics.0.relevance_score
0.333333
|
feed.11.topics.1.topic
Financial Markets
|
feed.11.topics.1.relevance_score
0.989041
|
feed.11.topics.3.topic
Energy & Transportation
|
feed.11.topics.3.relevance_score
0.333333
|
feed.11.topics.2.topic
Earnings
|
feed.11.topics.2.relevance_score
0.576289
|
feed.11.topics.4.topic
Technology
|
feed.11.topics.4.relevance_score
0.333333
|
feed.11.ticker_sentiment.0.ticker
AAL
|
feed.11.overall_sentiment_label
Neutral
|
feed.11.overall_sentiment_score
-0.01235
|
feed.11.ticker_sentiment.0.relevance_score
0.342803
|
feed.11.ticker_sentiment.0.ticker_sentiment_score
-0.200916
|
feed.11.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bearish
|
feed.11.ticker_sentiment.1.ticker
MNMD
|
feed.11.ticker_sentiment.1.relevance_score
0.140896
|
feed.11.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.11.ticker_sentiment.1.ticker_sentiment_score
0.246814
|
feed.11.ticker_sentiment.2.ticker
GME
|
feed.11.ticker_sentiment.2.relevance_score
0.277433
|
feed.11.ticker_sentiment.2.ticker_sentiment_score
0.216297
|
feed.11.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.12.title
Are Medical Stocks Lagging Mind Medicine MindMed  ( MNMD )  This Year?
|
feed.12.url
https://www.zacks.com/stock/news/2280546/are-medical-stocks-lagging-mind-medicine-mindmed-mnmd-this-year
|
feed.12.time_published
20240529T134012
|
feed.12.authors.0
Zacks Equity Research
|
feed.12.summary
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
|
feed.12.banner_image
https://staticx-tuner.zacks.com/images/default_article_images/default187.jpg
|
feed.12.source
Zacks Commentary
|
feed.12.category_within_source
n/a
|
feed.12.source_domain
www.zacks.com
|
feed.12.topics.0.topic
Life Sciences
|
feed.12.topics.0.relevance_score
0.5
|
feed.12.topics.1.topic
Financial Markets
|
feed.12.topics.1.relevance_score
0.266143
|
feed.12.topics.2.topic
Earnings
|
feed.12.topics.2.relevance_score
0.614606
|
feed.12.topics.3.topic
Technology
|
feed.12.topics.3.relevance_score
0.5
|
feed.12.overall_sentiment_score
0.215339
|
feed.12.overall_sentiment_label
Somewhat-Bullish
|
feed.12.ticker_sentiment.0.ticker
MNMD
|
feed.12.ticker_sentiment.0.relevance_score
0.708432
|
feed.12.ticker_sentiment.0.ticker_sentiment_score
0.343153
|
feed.12.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.12.ticker_sentiment.1.ticker
RMD
|
feed.12.ticker_sentiment.1.relevance_score
0.442082
|
feed.12.ticker_sentiment.1.ticker_sentiment_score
0.212773
|
feed.12.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.13.title
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing - Moderna  ( NASDAQ:MRNA ) 
|
feed.13.url
https://www.benzinga.com/news/24/05/38844468/jim-cramer-this-industrial-company-is-absolutely-terrific-recommends-buying-modine-manufacturing
|
feed.13.time_published
20240515T131811
|
feed.13.authors.0
Avi Kapoor
|
feed.13.summary
On CNBC's "Mad Money Lightning Round," Jim Cramer believes in Moderna, Inc. MRNA. On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna with an In-Line rating and announced a price target of $120. The "Mad Money" host likes Mind Medicine ( MindMed ) Inc.
|
feed.13.banner_image
https://cdn.benzinga.com/files/images/story/2024/05/15/JimCramer-Shutterstock.jpeg?width=1200&height=800&fit=crop
|
feed.13.source
Benzinga
|
feed.13.category_within_source
Trading
|
feed.13.source_domain
www.benzinga.com
|
feed.13.topics.0.topic
Life Sciences
|
feed.13.topics.0.relevance_score
0.25
|
feed.13.topics.1.topic
Manufacturing
|
feed.13.topics.1.relevance_score
0.25
|
feed.13.topics.2.topic
Technology
|
feed.13.overall_sentiment_score
0.16144
|
feed.13.overall_sentiment_label
Somewhat-Bullish
|
feed.13.ticker_sentiment.0.ticker
EVR
|
feed.13.ticker_sentiment.0.relevance_score
0.108466
|
feed.13.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.13.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.13.ticker_sentiment.1.ticker
MOD
|
feed.13.ticker_sentiment.1.relevance_score
0.317527
|
feed.13.ticker_sentiment.1.ticker_sentiment_score
0.606577
|
feed.13.ticker_sentiment.1.ticker_sentiment_label
Bullish
|
feed.13.ticker_sentiment.2.ticker
AME
|
feed.13.ticker_sentiment.2.relevance_score
0.414559
|
feed.13.ticker_sentiment.2.ticker_sentiment_score
0.206926
|
feed.13.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.13.ticker_sentiment.3.ticker
MNMD
|
feed.13.ticker_sentiment.3.relevance_score
0.317527
|
feed.13.ticker_sentiment.3.ticker_sentiment_score
-0.052286
|
feed.13.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.13.ticker_sentiment.4.ticker
MRNA
|
feed.13.ticker_sentiment.4.relevance_score
0.414559
|
feed.13.ticker_sentiment.4.ticker_sentiment_score
-0.056047
|
feed.13.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.13.ticker_sentiment.5.ticker
HTZ
|
feed.13.ticker_sentiment.5.relevance_score
0.317527
|
feed.13.ticker_sentiment.5.ticker_sentiment_score
-0.142995
|
feed.13.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.13.ticker_sentiment.6.ticker
PLTR
|
feed.13.ticker_sentiment.6.relevance_score
0.214937
|
feed.13.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.13.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.14.title
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Seritage Growth Props  ( NYSE:SRG ) 
|
feed.14.url
https://www.benzinga.com/news/24/05/38787830/seritage-growth-properties-posts-q1-loss-joins-fortrea-holdings-and-other-big-stocks-moving-lower-in
|
feed.14.time_published
20240513T123153
|
feed.14.authors.0
Avi Kapoor
|
feed.14.summary
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday. Shares of Seritage Growth Properties SRG fell sharply in today's pre-market trading after the company reported a loss for the first quarter.
|
feed.14.banner_image
https://cdn.benzinga.com/files/images/story/2024/05/13/Image26.jpeg?width=1200&height=800&fit=crop
|
feed.14.source
Benzinga
|
feed.14.category_within_source
Trading
|
feed.14.source_domain
www.benzinga.com
|
feed.14.topics.0.topic
Life Sciences
|
feed.14.topics.0.relevance_score
0.2
|
feed.14.topics.1.topic
Energy & Transportation
|
feed.14.topics.1.relevance_score
0.2
|
feed.14.topics.2.topic
Technology
|
feed.14.topics.2.relevance_score
0.2
|
feed.14.topics.3.topic
Finance
|
feed.14.topics.3.relevance_score
0.2
|
feed.14.topics.4.topic
Financial Markets
|
feed.14.topics.4.relevance_score
0.999998
|
feed.14.topics.5.topic
Earnings
|
feed.14.topics.5.relevance_score
0.857896
|
feed.14.overall_sentiment_score
-0.015013
|
feed.14.topics.6.topic
Real Estate & Construction
|
feed.14.topics.6.relevance_score
0.2
|
feed.14.ticker_sentiment.0.relevance_score
0.223866
|
feed.14.overall_sentiment_label
Neutral
|
feed.14.ticker_sentiment.0.ticker
FTRE
|
feed.13.topics.3.relevance_score
0.25
|
feed.14.ticker_sentiment.0.ticker_sentiment_score
-0.061788
|
feed.14.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.14.ticker_sentiment.1.ticker
MESO
|
feed.14.ticker_sentiment.1.relevance_score
0.223866
|
feed.14.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.14.ticker_sentiment.2.ticker
MKSI
|
feed.14.ticker_sentiment.2.relevance_score
0.223866
|
feed.14.ticker_sentiment.2.ticker_sentiment_score
-0.04978
|
feed.14.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.14.ticker_sentiment.3.ticker
PENN
|
feed.14.ticker_sentiment.3.relevance_score
0.330286
|
feed.14.ticker_sentiment.3.ticker_sentiment_score
0.009871
|
feed.14.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.14.ticker_sentiment.1.ticker_sentiment_score
0.176343
|
feed.14.ticker_sentiment.4.ticker
VTS
|
feed.14.ticker_sentiment.4.ticker_sentiment_label
Bearish
|
feed.14.ticker_sentiment.4.ticker_sentiment_score
-0.401538
|
feed.14.ticker_sentiment.4.relevance_score
0.330286
|
feed.14.ticker_sentiment.5.ticker
CIM
|
feed.14.ticker_sentiment.5.ticker_sentiment_score
-0.316608
|
feed.14.ticker_sentiment.5.ticker_sentiment_label
Somewhat-Bearish
|
feed.14.ticker_sentiment.5.relevance_score
0.330286
|
feed.14.ticker_sentiment.6.ticker
KEP
|
feed.14.ticker_sentiment.6.ticker_sentiment_score
-0.319602
|
feed.14.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bearish
|
feed.14.ticker_sentiment.6.relevance_score
0.223866
|
feed.14.ticker_sentiment.7.ticker
MNMD
|
feed.14.ticker_sentiment.7.ticker_sentiment_score
-0.090682
|
feed.14.ticker_sentiment.7.relevance_score
0.223866
|
feed.14.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.14.ticker_sentiment.8.relevance_score
0.223866
|
feed.14.ticker_sentiment.8.ticker_sentiment_score
0.03271
|
feed.14.ticker_sentiment.8.ticker
BUR
|
feed.14.ticker_sentiment.8.ticker_sentiment_label
Neutral
|
feed.14.ticker_sentiment.9.relevance_score
0.223866
|
feed.14.ticker_sentiment.9.ticker
SRG-P-A
|
feed.14.ticker_sentiment.9.ticker_sentiment_score
-0.14856
|
feed.15.title
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
|
feed.14.ticker_sentiment.9.ticker_sentiment_label
Neutral
|
feed.15.url
https://www.fool.com/investing/2024/04/25/this-small-cap-stock-is-up-150-this-year-and-heres/
|
feed.15.authors.0
David Jagielski
|
feed.15.time_published
20240425T093700
|
feed.15.summary
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
|
feed.15.source
Motley Fool
|
feed.15.category_within_source
n/a
|
feed.15.banner_image
https://media.ycharts.com/charts/887c4d12055417c81c6d752c80b64f41.png
|
feed.15.source_domain
www.fool.com
|
feed.15.topics.0.relevance_score
0.5
|
feed.15.topics.1.topic
Technology
|
feed.15.topics.0.topic
Life Sciences
|
feed.15.topics.1.relevance_score
0.5
|
feed.15.topics.2.relevance_score
0.503496
|
feed.15.topics.2.topic
Financial Markets
|
feed.15.overall_sentiment_score
0.28068
|
feed.15.ticker_sentiment.0.ticker
MNMD
|
feed.15.ticker_sentiment.0.relevance_score
0.575728
|
feed.15.overall_sentiment_label
Somewhat-Bullish
|
feed.15.ticker_sentiment.0.ticker_sentiment_score
0.317542
|
feed.15.ticker_sentiment.1.ticker
JNJ
|
feed.15.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.15.ticker_sentiment.1.relevance_score
0.057907
|
feed.15.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.16.url
https://www.benzinga.com/general/24/04/38341401/jim-cramer-slams-political-blocking-of-lsd-derived-antidepressants-citing-strong-test-data-showing-t
|
feed.16.title
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' - ATAI Life Sciences  ( NASDAQ:ATAI ) , Compass Pathways  ( NASDAQ:CMPS ) 
|
feed.15.ticker_sentiment.1.ticker_sentiment_score
0.127985
|
feed.16.authors.0
Caleb Naysmith
|
feed.16.time_published
20240419T192320
|
feed.16.summary
Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain â¦ LSD," and he made sure his interview did not disappoint. Mind Medicine Inc.
|
feed.16.source
Benzinga
|
feed.16.category_within_source
General
|
feed.16.source_domain
www.benzinga.com
|
feed.16.banner_image
https://cdn.benzinga.com/files/images/story/2024/04/19/Jim-Cramer-Photo-by-s-bukley-on-Shutters.jpeg?width=1200&height=800&fit=crop
|
feed.16.topics.0.topic
Life Sciences
|
feed.16.topics.1.topic
Technology
|
feed.16.topics.1.relevance_score
0.5
|
feed.16.topics.0.relevance_score
0.5
|
feed.16.topics.2.topic
Financial Markets
|
feed.16.overall_sentiment_score
0.214974
|
feed.16.topics.2.relevance_score
0.161647
|
feed.16.overall_sentiment_label
Somewhat-Bullish
|
feed.16.ticker_sentiment.0.relevance_score
0.07423
|
feed.16.ticker_sentiment.0.ticker
META
|
feed.16.ticker_sentiment.0.ticker_sentiment_score
0.167726
|
feed.16.ticker_sentiment.1.ticker
CMPS
|
feed.16.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.16.ticker_sentiment.1.relevance_score
0.147818
|
feed.16.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.16.ticker_sentiment.1.ticker_sentiment_score
0.109381
|
feed.16.ticker_sentiment.2.ticker
MNMD
|
feed.13.topics.2.relevance_score
0.25
|
feed.16.ticker_sentiment.2.ticker_sentiment_score
-0.188343
|
feed.16.ticker_sentiment.2.relevance_score
0.147818
|
feed.16.ticker_sentiment.3.ticker
EBAY
|
feed.16.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bearish
|
feed.16.ticker_sentiment.3.ticker_sentiment_score
0.221569
|
feed.16.ticker_sentiment.3.relevance_score
0.07423
|
feed.16.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.16.ticker_sentiment.4.ticker
UBER
|
feed.16.ticker_sentiment.4.relevance_score
0.07423
|
feed.16.ticker_sentiment.4.ticker_sentiment_score
0.167726
|
feed.16.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.17.title
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday - Roblox  ( NYSE:RBLX ) 
|
feed.17.time_published
20240410T145611
|
feed.17.url
https://www.benzinga.com/news/24/04/38185041/roblox-tal-education-and-other-big-stocks-moving-higher-on-wednesday
|
feed.17.authors.0
Avi Kapoor
|
feed.17.summary
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday. Shares of Roblox Corporation RBLX rose during Wednesday's session following reports the company has ramped up efforts to attract advertisers to its platform and made other moves to boost advertising sales.
|
feed.17.source
Benzinga
|
feed.17.category_within_source
Trading
|
feed.17.source_domain
www.benzinga.com
|
feed.17.banner_image
https://cdn.benzinga.com/files/images/story/2024/04/10/image14_0.jpg?width=1200&height=800&fit=crop
|
feed.17.topics.0.topic
Life Sciences
|
feed.17.topics.1.topic
Financial Markets
|
feed.17.topics.1.relevance_score
0.161647
|
feed.17.topics.2.topic
Manufacturing
|
feed.17.topics.0.relevance_score
0.333333
|
feed.13.topics.3.topic
Finance
|
feed.17.topics.2.relevance_score
0.333333
|
feed.17.topics.3.relevance_score
0.158519
|
feed.17.topics.3.topic
Earnings
|
feed.17.topics.4.relevance_score
0.333333
|
feed.17.overall_sentiment_score
0.221437
|
feed.17.ticker_sentiment.0.ticker
ACB
|
feed.17.ticker_sentiment.0.relevance_score
0.249106
|
feed.17.overall_sentiment_label
Somewhat-Bullish
|
feed.17.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.17.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.1.ticker_sentiment_score
0.579639
|
feed.17.ticker_sentiment.1.relevance_score
0.249106
|
feed.17.ticker_sentiment.1.ticker
MRNO
|
feed.17.ticker_sentiment.1.ticker_sentiment_label
Bullish
|
feed.17.ticker_sentiment.2.ticker
ILST
|
feed.17.ticker_sentiment.2.ticker_sentiment_score
0.0
|
feed.17.topics.4.topic
Technology
|
feed.17.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.3.ticker
OFLX
|
feed.17.ticker_sentiment.2.relevance_score
0.126119
|
feed.17.ticker_sentiment.3.ticker_sentiment_label
Bullish
|
feed.17.ticker_sentiment.3.ticker_sentiment_score
0.579639
|
feed.17.ticker_sentiment.4.ticker
EAF
|
feed.17.ticker_sentiment.4.ticker_sentiment_score
0.0
|
feed.17.ticker_sentiment.4.relevance_score
0.249106
|
feed.17.ticker_sentiment.3.relevance_score
0.249106
|
feed.17.ticker_sentiment.5.ticker
NVX
|
feed.17.ticker_sentiment.5.relevance_score
0.249106
|
feed.17.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.6.ticker
APLD
|
feed.17.ticker_sentiment.5.ticker_sentiment_label
Bearish
|
feed.17.ticker_sentiment.6.ticker_sentiment_score
0.208377
|
feed.17.ticker_sentiment.6.relevance_score
0.366061
|
feed.17.ticker_sentiment.7.ticker
RBLX
|
feed.17.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bullish
|
feed.17.ticker_sentiment.5.ticker_sentiment_score
-0.42797
|
feed.17.ticker_sentiment.7.ticker_sentiment_score
0.600798
|
feed.17.ticker_sentiment.7.relevance_score
0.366061
|
feed.17.ticker_sentiment.7.ticker_sentiment_label
Bullish
|
feed.17.ticker_sentiment.8.ticker
MNMD
|
feed.17.ticker_sentiment.8.relevance_score
0.249106
|
feed.17.ticker_sentiment.8.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.9.ticker
IZM
|
feed.17.ticker_sentiment.9.ticker_sentiment_score
0.0
|
feed.17.ticker_sentiment.9.relevance_score
0.249106
|
feed.17.ticker_sentiment.9.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.10.relevance_score
0.249106
|
feed.17.ticker_sentiment.10.ticker
RVMD
|
feed.17.ticker_sentiment.10.ticker_sentiment_score
0.579639
|
feed.17.ticker_sentiment.8.ticker_sentiment_score
0.0
|
feed.17.ticker_sentiment.10.ticker_sentiment_label
Bullish
|
feed.17.ticker_sentiment.11.relevance_score
0.249106
|
feed.17.ticker_sentiment.11.ticker
DOGZ
|
feed.17.ticker_sentiment.11.ticker_sentiment_label
Bullish
|
feed.17.ticker_sentiment.12.ticker
TAL
|
feed.17.ticker_sentiment.12.ticker_sentiment_score
0.0
|
feed.17.ticker_sentiment.12.relevance_score
0.366061
|
feed.17.ticker_sentiment.12.ticker_sentiment_label
Neutral
|
feed.17.ticker_sentiment.13.ticker
FUFU
|
feed.17.ticker_sentiment.13.relevance_score
0.366061
|
feed.17.ticker_sentiment.13.ticker_sentiment_score
0.203515
|
feed.17.ticker_sentiment.13.ticker_sentiment_label
Somewhat-Bullish
|
feed.17.ticker_sentiment.14.ticker
TSHA
|
feed.17.ticker_sentiment.14.relevance_score
0.249106
|
feed.17.ticker_sentiment.14.ticker_sentiment_score
-0.179874
|
feed.17.ticker_sentiment.14.ticker_sentiment_label
Somewhat-Bearish
|
feed.18.title
MindMed  ( MNMD )  Stock Rises 154% in 3 Months: Here's Why
|
feed.18.url
https://www.zacks.com/stock/news/2251672/mindmed-mnmd-stock-rises-154-in-3-months-heres-why
|
feed.17.ticker_sentiment.11.ticker_sentiment_score
0.353246
|
feed.18.time_published
20240408T105900
|
feed.18.summary
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
|
feed.18.authors.0
Zacks Equity Research
|
feed.18.banner_image
https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg
|
feed.18.category_within_source
n/a
|
feed.18.source
Zacks Commentary
|
feed.18.topics.0.topic
Earnings
|
feed.18.topics.1.topic
Life Sciences
|
feed.18.topics.0.relevance_score
0.928139
|
feed.18.topics.1.relevance_score
0.5
|
feed.18.topics.2.topic
Technology
|
feed.18.overall_sentiment_score
0.269652
|
feed.18.topics.2.relevance_score
0.5
|
feed.18.overall_sentiment_label
Somewhat-Bullish
|
feed.18.source_domain
www.zacks.com
|
feed.18.ticker_sentiment.0.ticker
ADMA
|
feed.18.ticker_sentiment.0.relevance_score
0.307924
|
feed.18.ticker_sentiment.0.ticker_sentiment_score
0.257048
|
feed.18.ticker_sentiment.1.ticker
ANIP
|
feed.18.ticker_sentiment.1.relevance_score
0.379435
|
feed.18.ticker_sentiment.1.ticker_sentiment_score
0.301767
|
feed.18.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.18.ticker_sentiment.2.ticker
LGND
|
feed.18.ticker_sentiment.2.ticker_sentiment_score
0.306728
|
feed.18.ticker_sentiment.2.relevance_score
0.307924
|
feed.18.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.18.ticker_sentiment.3.ticker
MNMD
|
feed.18.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.18.ticker_sentiment.3.relevance_score
0.379435
|
feed.18.ticker_sentiment.3.ticker_sentiment_score
0.031392
|
feed.18.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.19.url
https://www.benzinga.com/news/24/04/38085469/simulations-plus-posts-upbeat-joins-levi-strauss-blackberry-and-other-big-stocks-moving-higher-in-th
|
feed.19.authors.0
Avi Kapoor
|
feed.19.time_published
20240404T091840
|
feed.19.summary
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. Shares of Simulations Plus, Inc. SLP rose sharply in today's pre-market trading after the company posted better-than-expected results for its second quarter.
|
feed.19.banner_image
https://cdn.benzinga.com/files/images/story/2024/04/04/image27.jpeg?width=1200&height=800&fit=crop
|
feed.19.source
Benzinga
|
feed.19.title
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session - BlackBerry  ( NYSE:BB ) , Simulations Plus  ( NASDAQ:SLP ) , Levi Strauss  ( NYSE:LEVI ) 
|
feed.19.source_domain
www.benzinga.com
|
feed.19.topics.0.topic
Life Sciences
|
feed.19.topics.1.topic
Financial Markets
|
feed.19.topics.1.relevance_score
0.623304
|
feed.19.topics.2.topic
Manufacturing
|
feed.19.topics.2.relevance_score
0.333333
|
feed.19.topics.3.topic
Earnings
|
feed.19.topics.3.relevance_score
0.96136
|
feed.19.topics.4.topic
Technology
|
feed.19.category_within_source
Trading
|
feed.19.topics.4.relevance_score
0.333333
|
feed.19.overall_sentiment_score
0.337622
|
feed.19.overall_sentiment_label
Somewhat-Bullish
|
feed.19.ticker_sentiment.0.ticker
ACB
|
feed.19.ticker_sentiment.0.relevance_score
0.231332
|
feed.19.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.19.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.19.ticker_sentiment.1.ticker
BB
|
feed.19.ticker_sentiment.1.relevance_score
0.231332
|
feed.19.ticker_sentiment.1.ticker_sentiment_score
0.007329
|
feed.19.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.19.ticker_sentiment.2.ticker
MGNX
|
feed.19.ticker_sentiment.2.relevance_score
0.340915
|
feed.19.ticker_sentiment.2.ticker_sentiment_score
0.0
|
feed.19.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.19.ticker_sentiment.3.ticker
CRON
|
feed.19.ticker_sentiment.3.relevance_score
0.231332
|
feed.19.ticker_sentiment.3.ticker_sentiment_score
0.485165
|
feed.19.ticker_sentiment.4.ticker
DXYZ
|
feed.19.ticker_sentiment.4.relevance_score
0.231332
|
feed.19.ticker_sentiment.4.ticker_sentiment_score
0.234558
|
feed.19.ticker_sentiment.3.ticker_sentiment_label
Bullish
|
feed.19.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.19.ticker_sentiment.5.ticker
SLP
|
feed.19.ticker_sentiment.5.relevance_score
0.443626
|
feed.19.ticker_sentiment.5.ticker_sentiment_score
0.360333
|
feed.19.ticker_sentiment.6.ticker
LW
|
feed.19.ticker_sentiment.5.ticker_sentiment_label
Bullish
|
feed.19.ticker_sentiment.6.relevance_score
0.231332
|
feed.19.ticker_sentiment.6.ticker_sentiment_score
0.30494
|
feed.19.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bullish
|
feed.19.ticker_sentiment.7.ticker
MNMD
|
feed.19.ticker_sentiment.7.relevance_score
0.231332
|
feed.19.ticker_sentiment.7.ticker_sentiment_score
0.266619
|
feed.19.ticker_sentiment.7.ticker_sentiment_label
Somewhat-Bullish
|
feed.20.time_published
20240402T113000
|
feed.20.title
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract - Optimi Health  ( OTC:OPTHF ) 
|
feed.20.url
https://www.benzinga.com/pressreleases/24/04/g38042222/optimi-health-receives-finished-product-test-results-and-certificate-of-analysis-for-gmp-natural-p
|
feed.20.authors.0
Globe Newswire
|
feed.20.summary
VANCOUVER, British Columbia, April 02, 2024 ( GLOBE NEWSWIRE ) -- Optimi Health Corp.
|
feed.20.banner_image
https://www.benzinga.com/next-assets/images/schema-image-default.png
|
feed.20.source
Benzinga
|
feed.20.category_within_source
General
|
feed.20.source_domain
www.benzinga.com
|
feed.20.topics.0.topic
Technology
|
feed.20.topics.0.relevance_score
1.0
|
feed.20.overall_sentiment_score
0.337108
|
feed.20.overall_sentiment_label
Somewhat-Bullish
|
feed.20.ticker_sentiment.0.ticker
MNMD
|
feed.20.ticker_sentiment.0.relevance_score
0.046724
|
feed.20.ticker_sentiment.0.ticker_sentiment_score
0.101677
|
feed.20.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.21.title
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
|
feed.21.url
https://www.globenewswire.com/news-release/2024/03/28/2853901/0/en/Optimi-Health-Confirms-Presenting-Sponsorship-at-the-4th-Annual-Psychedelic-Therapeutics-and-Drug-Development-Conference.html
|
feed.21.time_published
20240328T113000
|
feed.21.authors.0
Optimi Health Corp.
|
feed.21.summary
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
|
feed.21.banner_image
https://ml.globenewswire.com/Resource/Download/5e3d5f3e-3e70-4e6f-9c1f-78ee2a1df6ee
|
feed.21.source
GlobeNewswire
|
feed.21.category_within_source
n/a
|
feed.21.source_domain
www.globenewswire.com
|
feed.21.topics.0.topic
Real Estate & Construction
|
feed.21.topics.0.relevance_score
0.5
|
feed.21.topics.1.topic
Technology
|
feed.21.topics.1.relevance_score
0.5
|
feed.21.topics.2.topic
Financial Markets
|
feed.21.topics.2.relevance_score
0.360215
|
feed.21.overall_sentiment_score
0.268855
|
feed.21.ticker_sentiment.0.ticker
APG
|
feed.21.overall_sentiment_label
Somewhat-Bullish
|
feed.21.ticker_sentiment.0.relevance_score
0.118064
|
feed.21.ticker_sentiment.0.ticker_sentiment_score
0.137405
|
feed.21.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.21.ticker_sentiment.1.ticker
MNMD
|
feed.21.ticker_sentiment.1.relevance_score
0.059194
|
feed.21.ticker_sentiment.1.ticker_sentiment_score
0.141001
|
feed.21.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.22.url
https://moneymorning.com/2024/03/27/mindmeds-set-to-pass-a-psychological-market-test/
|
feed.22.title
MindMed's Set to Pass a Psychological Market Test
|
feed.22.time_published
20240327T151217
|
feed.22.authors.0
Chris Johnson
|
feed.22.source
Money Morning
|
feed.22.summary
It's a little ironic ( strangely I hear Alanis Morissette singing that as I type ) that I'm talking about psychological levels with a psychedelic stock. Shares of Mind Medicine ( MNMD ) are preparing for one of the biggest moves a stock under $10 can make. The stock is setting up for a ...
|
feed.22.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/DALL%C2%B7E-2024-03-27-11.11.21-A-panoramic-image-visualizing-an-abstract-stock-chart-for-Mind-Medicine-Inc-showing-a-long-period-of-fluctuation-with-minimal-growth-followed-by-a-1200x686.png
|
feed.22.category_within_source
GoogleRSS
|
feed.22.source_domain
moneymorning.com
|
feed.22.topics.0.topic
Technology
|
feed.22.topics.0.relevance_score
1.0
|
feed.22.topics.1.topic
Financial Markets
|
feed.22.topics.1.relevance_score
0.779048
|
feed.22.overall_sentiment_score
0.119011
|
feed.22.overall_sentiment_label
Neutral
|
feed.22.ticker_sentiment.0.ticker
MNMD
|
feed.22.ticker_sentiment.0.relevance_score
0.233556
|
feed.22.ticker_sentiment.0.ticker_sentiment_score
0.155259
|
feed.22.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.23.time_published
20240327T142556
|
feed.23.title
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.23.url
https://www.benzinga.com/general/biotech/24/03/37960454/podcast-lsd-deserves-to-reclaim-its-spot-at-the-lead-of-the-path-for-psychedelics-says-mindmeds-r
|
feed.23.authors.0
Lara Goldstein
|
feed.23.summary
Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined by Robert Barrow, CEO of Mind Medicine ( MindMed ) MNMD, which has taken the development of LSD-based therapy to new heights.
|
feed.23.banner_image
https://cdn.benzinga.com/files/images/story/2024/Rob-Headshot-2023.jpeg?width=1200&height=800&fit=crop
|
feed.23.source
Benzinga
|
feed.23.category_within_source
News
|
feed.23.source_domain
www.benzinga.com
|
feed.23.topics.0.topic
Technology
|
feed.23.topics.0.relevance_score
1.0
|
feed.23.overall_sentiment_score
0.097665
|
feed.23.overall_sentiment_label
Neutral
|
feed.23.ticker_sentiment.0.ticker
MNMD
|
feed.23.ticker_sentiment.0.relevance_score
0.227007
|
feed.23.ticker_sentiment.0.ticker_sentiment_score
0.188734
|
feed.23.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.23.ticker_sentiment.1.ticker
SPOT
|
feed.23.ticker_sentiment.1.relevance_score
0.152499
|
feed.23.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.23.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.24.title
Cybin  ( CYBN )  Begins Phase II Study on Anxiety Drug, Stock Up
|
feed.24.url
https://www.zacks.com/stock/news/2242293/cybin-cybn-begins-phase-ii-study-on-anxiety-drug-stock-up
|
feed.24.time_published
20240318T152300
|
feed.24.authors.0
Kanishka Das
|
feed.24.summary
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
|
feed.24.banner_image
https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg
|
feed.24.source
Zacks Commentary
|
feed.24.category_within_source
n/a
|
feed.24.source_domain
www.zacks.com
|
feed.24.topics.0.topic
Earnings
|
feed.24.topics.0.relevance_score
0.972193
|
feed.24.topics.1.topic
Life Sciences
|
feed.24.topics.2.topic
Technology
|
feed.24.topics.1.relevance_score
0.5
|
feed.24.topics.2.relevance_score
0.5
|
feed.24.ticker_sentiment.0.ticker
ADMA
|
feed.24.overall_sentiment_score
0.128044
|
feed.24.overall_sentiment_label
Neutral
|
feed.24.ticker_sentiment.0.relevance_score
0.398148
|
feed.24.ticker_sentiment.0.ticker_sentiment_score
0.287107
|
feed.24.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.24.ticker_sentiment.1.ticker
ANIP
|
feed.24.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.24.ticker_sentiment.1.relevance_score
0.398148
|
feed.24.ticker_sentiment.1.ticker_sentiment_score
0.29952
|
feed.24.ticker_sentiment.2.ticker_sentiment_score
0.104406
|
feed.24.ticker_sentiment.2.ticker
FGROF
|
feed.24.ticker_sentiment.2.relevance_score
0.069294
|
feed.24.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.24.ticker_sentiment.3.ticker
MNMD
|
feed.24.ticker_sentiment.3.ticker_sentiment_score
0.097896
|
feed.24.ticker_sentiment.3.relevance_score
0.205807
|
feed.24.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.19.topics.0.relevance_score
0.333333
|
feed.24.ticker_sentiment.4.relevance_score
0.398148
|
feed.24.ticker_sentiment.4.ticker_sentiment_score
0.152215
|
feed.24.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.25.title
Cortexa Leads the World in First Supply of Psilocybin Under the TGA's Authorized Prescriber Scheme
|
feed.25.url
https://www.globenewswire.com/news-release/2024/03/18/2847819/0/en/Cortexa-Leads-the-World-in-First-Supply-of-Psilocybin-Under-the-TGA-s-Authorized-Prescriber-Scheme.html
|
feed.25.time_published
20240318T125500
|
feed.25.authors.0
PharmAla Biotech
|
feed.25.summary
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme ...
|
feed.25.banner_image
https://ml.globenewswire.com/Resource/Download/20158980-8674-43e3-a0be-a10dca42410d
|
feed.25.source
GlobeNewswire
|
feed.25.category_within_source
n/a
|
feed.25.source_domain
www.globenewswire.com
|
feed.25.topics.0.topic
Technology
|
feed.25.topics.0.relevance_score
1.0
|
feed.25.topics.1.topic
Financial Markets
|
feed.25.topics.1.relevance_score
0.158519
|
feed.25.overall_sentiment_score
0.135973
|
feed.25.overall_sentiment_label
Neutral
|
feed.25.ticker_sentiment.0.ticker
MNMD
|
feed.25.ticker_sentiment.0.relevance_score
0.048919
|
feed.25.ticker_sentiment.0.ticker_sentiment_score
0.147992
|
feed.25.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.26.title
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Robinhood Markets  ( NASDAQ:HOOD ) 
|
feed.26.url
https://www.benzinga.com/news/24/03/37693963/why-robinhood-shares-are-trading-higher-by-around-12-here-are-20-stocks-moving-premarket
|
feed.26.time_published
20240314T120543
|
feed.26.authors.0
Avi Kapoor
|
feed.26.summary
Shares of Robinhood Markets, Inc. HOOD rose sharply in today's pre-market trading after the company reported February trading metrics. After the market close on Wednesday, Robinhood said total funded customers grew to 23.6 million at the end of February, up approximately 130,000 from January.
|
feed.26.banner_image
https://cdn.benzinga.com/files/images/story/2024/03/14/robinhood_markets_-_logo.jpg?width=1200&height=800&fit=crop
|
feed.26.source
Benzinga
|
feed.26.category_within_source
Trading
|
feed.26.source_domain
www.benzinga.com
|
feed.26.topics.0.topic
Life Sciences
|
feed.26.topics.0.relevance_score
0.166667
|
feed.26.topics.1.topic
Technology
|
feed.26.topics.1.relevance_score
0.166667
|
feed.26.topics.2.topic
Finance
|
feed.26.topics.2.relevance_score
0.166667
|
feed.26.topics.3.topic
Retail & Wholesale
|
feed.26.topics.3.relevance_score
0.166667
|
feed.26.topics.4.topic
Financial Markets
|
feed.26.topics.4.relevance_score
0.882182
|
feed.26.topics.5.topic
Manufacturing
|
feed.26.topics.5.relevance_score
0.166667
|
feed.26.topics.6.topic
Earnings
|
feed.26.topics.6.relevance_score
0.614606
|
feed.26.topics.7.topic
Mergers & Acquisitions
|
feed.26.topics.7.relevance_score
0.158519
|
feed.26.topics.8.topic
Real Estate & Construction
|
feed.26.topics.8.relevance_score
0.166667
|
feed.26.overall_sentiment_score
0.101552
|
feed.26.overall_sentiment_label
Neutral
|
feed.26.ticker_sentiment.0.ticker
MOMO
|
feed.26.ticker_sentiment.0.relevance_score
0.148273
|
feed.26.ticker_sentiment.0.ticker_sentiment_score
-0.05719
|
feed.26.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.1.ticker
HOVR
|
feed.26.ticker_sentiment.1.relevance_score
0.148273
|
feed.26.ticker_sentiment.1.ticker_sentiment_score
0.321521
|
feed.26.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.2.ticker
PGY
|
feed.26.ticker_sentiment.2.relevance_score
0.148273
|
feed.26.ticker_sentiment.2.ticker_sentiment_score
-0.045428
|
feed.26.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.3.ticker
FSR
|
feed.26.ticker_sentiment.3.relevance_score
0.220809
|
feed.26.ticker_sentiment.3.ticker_sentiment_score
-0.373357
|
feed.26.ticker_sentiment.3.ticker_sentiment_label
Bearish
|
feed.26.ticker_sentiment.4.ticker
PRST
|
feed.24.ticker_sentiment.4.ticker
VNDA
|
feed.26.ticker_sentiment.5.ticker
NHGP
|
feed.26.ticker_sentiment.5.relevance_score
0.07446
|
feed.26.ticker_sentiment.5.ticker_sentiment_score
0.258298
|
feed.26.ticker_sentiment.5.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.6.ticker
STI
|
feed.26.ticker_sentiment.6.relevance_score
0.220809
|
feed.26.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.26.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.7.ticker
SPRB
|
feed.26.ticker_sentiment.7.relevance_score
0.148273
|
feed.26.ticker_sentiment.7.ticker_sentiment_score
-0.129845
|
feed.26.ticker_sentiment.4.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.8.ticker
CCTG
|
feed.26.ticker_sentiment.8.relevance_score
0.148273
|
feed.26.ticker_sentiment.8.ticker_sentiment_score
0.068822
|
feed.26.ticker_sentiment.8.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.4.relevance_score
0.148273
|
feed.26.ticker_sentiment.9.ticker
HEAR
|
feed.26.ticker_sentiment.9.relevance_score
0.148273
|
feed.26.ticker_sentiment.9.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.9.ticker_sentiment_score
0.153926
|
feed.26.ticker_sentiment.10.ticker
QLI
|
feed.26.ticker_sentiment.10.ticker_sentiment_label
Somewhat-Bearish
|
feed.26.ticker_sentiment.10.ticker_sentiment_score
-0.183045
|
feed.26.ticker_sentiment.11.ticker
HGAS
|
feed.26.ticker_sentiment.11.relevance_score
0.148273
|
feed.26.ticker_sentiment.11.ticker_sentiment_score
-0.059895
|
feed.26.ticker_sentiment.12.relevance_score
0.148273
|
feed.26.ticker_sentiment.12.ticker
VRM
|
feed.26.ticker_sentiment.12.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.13.ticker
FUTU
|
feed.26.ticker_sentiment.11.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.10.relevance_score
0.148273
|
feed.26.ticker_sentiment.12.ticker_sentiment_score
-0.02809
|
feed.26.ticker_sentiment.13.ticker_sentiment_score
-0.203681
|
feed.26.ticker_sentiment.13.ticker_sentiment_label
Somewhat-Bearish
|
feed.26.ticker_sentiment.14.ticker
RAYA
|
feed.26.ticker_sentiment.14.relevance_score
0.148273
|
feed.26.ticker_sentiment.14.ticker_sentiment_score
-0.237468
|
feed.26.ticker_sentiment.14.ticker_sentiment_label
Somewhat-Bearish
|
feed.26.ticker_sentiment.15.ticker
MNMD
|
feed.26.ticker_sentiment.15.relevance_score
0.148273
|
feed.26.ticker_sentiment.15.ticker_sentiment_score
0.188142
|
feed.26.ticker_sentiment.15.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.13.relevance_score
0.148273
|
feed.26.ticker_sentiment.16.ticker
SPRO
|
feed.26.ticker_sentiment.16.relevance_score
0.148273
|
feed.26.ticker_sentiment.16.ticker_sentiment_score
0.296558
|
feed.26.ticker_sentiment.16.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.17.ticker
AUUD
|
feed.26.ticker_sentiment.17.relevance_score
0.148273
|
feed.26.ticker_sentiment.18.relevance_score
0.220809
|
feed.26.ticker_sentiment.17.ticker_sentiment_label
Somewhat-Bullish
|
feed.26.ticker_sentiment.17.ticker_sentiment_score
0.232402
|
feed.26.ticker_sentiment.18.ticker
HOOD
|
feed.26.ticker_sentiment.19.ticker
PIXY
|
feed.26.ticker_sentiment.18.ticker_sentiment_score
0.148819
|
feed.26.ticker_sentiment.18.ticker_sentiment_label
Neutral
|
feed.26.ticker_sentiment.19.ticker_sentiment_label
Bullish
|
feed.26.ticker_sentiment.19.relevance_score
0.148273
|
feed.26.ticker_sentiment.19.ticker_sentiment_score
0.368546
|
feed.27.title
Three Stocks: MindMed, Tesla, and Dollar Tree
|
feed.27.url
https://moneymorning.com/2024/03/13/three-stocks-mindmed-tesla-and-dollar-tree/
|
feed.27.time_published
20240313T150359
|
feed.27.authors.0
Chris Johnson
|
feed.27.summary
What a ride it has been for Mind Medicine ( MNMD ) investors. We saw the stock shoot through the sky last week on news that the FDA had granted "Breakthrough Therapy Designation" to one of the company's trial treatments, but then shares dropped 30% from their highs.
|
feed.27.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2018/11/Retina_Headshots_ChrisJohnson.jpg
|
feed.27.topics.0.topic
Retail & Wholesale
|
feed.27.source
Money Morning
|
feed.27.category_within_source
RSS
|
feed.27.topics.0.relevance_score
0.25
|
feed.27.source_domain
moneymorning.com
|
feed.27.topics.2.topic
Manufacturing
|
feed.27.topics.1.topic
Financial Markets
|
feed.27.topics.1.relevance_score
0.413559
|
feed.27.topics.2.relevance_score
0.25
|
feed.27.topics.3.relevance_score
0.839681
|
feed.27.topics.4.topic
Technology
|
feed.27.topics.4.relevance_score
0.25
|
feed.27.topics.5.topic
Finance
|
feed.27.topics.5.relevance_score
0.25
|
feed.27.overall_sentiment_score
-0.148876
|
feed.27.overall_sentiment_label
Neutral
|
feed.27.ticker_sentiment.0.ticker
TGT
|
feed.27.ticker_sentiment.0.relevance_score
0.19661
|
feed.27.ticker_sentiment.0.ticker_sentiment_score
0.201257
|
feed.27.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.27.ticker_sentiment.1.ticker
DG
|
feed.27.topics.3.topic
Earnings
|
feed.27.ticker_sentiment.1.relevance_score
0.19661
|
feed.27.ticker_sentiment.1.ticker_sentiment_score
0.19519
|
feed.27.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.27.ticker_sentiment.2.ticker
TSLA
|
feed.27.ticker_sentiment.2.relevance_score
0.381463
|
feed.27.ticker_sentiment.2.ticker_sentiment_score
-0.537764
|
feed.27.ticker_sentiment.3.relevance_score
0.099066
|
feed.27.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bearish
|
feed.27.ticker_sentiment.4.ticker
DLTR
|
feed.27.ticker_sentiment.4.relevance_score
0.381463
|
feed.27.ticker_sentiment.4.ticker_sentiment_score
-0.089691
|
feed.27.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.27.ticker_sentiment.5.ticker
MNMD
|
feed.27.ticker_sentiment.5.relevance_score
0.291182
|
feed.27.ticker_sentiment.5.ticker_sentiment_score
0.193328
|
feed.27.ticker_sentiment.5.ticker_sentiment_label
Somewhat-Bullish
|
feed.27.ticker_sentiment.6.relevance_score
0.19661
|
feed.27.ticker_sentiment.6.ticker_sentiment_score
0.201257
|
feed.27.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bullish
|
feed.28.title
Three Stocks: MindMed, Tesla, and Dollar Tree
|
feed.26.ticker_sentiment.4.ticker_sentiment_score
0.171671
|
feed.28.time_published
20240313T070000
|
feed.28.authors.0
Chris Johnson
|
feed.27.ticker_sentiment.6.ticker
WMT
|
feed.28.summary
What a ride it has been for Mind Medicine ( MNMD ) investors. We saw the stock shoot through the sky last week on news that the FDA had granted "Breakthrough Therapy Designation" to one of the company's trial treatments, but then shares dropped 30% from their highs.
|
feed.28.banner_image

|
feed.27.ticker_sentiment.2.ticker_sentiment_label
Bearish
|
feed.27.ticker_sentiment.3.ticker_sentiment_score
-0.318308
|
feed.27.ticker_sentiment.3.ticker
WFC
|
feed.28.source
Money Morning
|
feed.28.category_within_source
GoogleRSS
|
feed.28.source_domain
moneymorning.com
|
feed.28.topics.0.relevance_score
0.25
|
feed.28.topics.1.relevance_score
0.413559
|
feed.28.topics.1.topic
Financial Markets
|
feed.28.topics.0.topic
Retail & Wholesale
|
feed.28.topics.2.topic
Manufacturing
|
feed.28.topics.2.relevance_score
0.25
|
feed.28.topics.4.relevance_score
0.25
|
feed.28.topics.3.topic
Earnings
|
feed.28.topics.3.relevance_score
0.839681
|
feed.28.topics.4.topic
Technology
|
feed.28.topics.5.topic
Finance
|
feed.28.topics.5.relevance_score
0.25
|
feed.28.overall_sentiment_score
-0.148876
|
feed.28.overall_sentiment_label
Neutral
|
feed.28.ticker_sentiment.0.ticker
TGT
|
feed.28.ticker_sentiment.0.relevance_score
0.19661
|
feed.28.ticker_sentiment.0.ticker_sentiment_score
0.201257
|
feed.28.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.28.ticker_sentiment.1.ticker
DG
|
feed.28.ticker_sentiment.1.relevance_score
0.19661
|
feed.28.ticker_sentiment.1.ticker_sentiment_score
0.19519
|
feed.28.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.28.ticker_sentiment.2.ticker
TSLA
|
feed.28.ticker_sentiment.2.relevance_score
0.381463
|
feed.28.ticker_sentiment.2.ticker_sentiment_score
-0.537764
|
feed.28.ticker_sentiment.2.ticker_sentiment_label
Bearish
|
feed.28.ticker_sentiment.3.ticker
WFC
|
feed.28.ticker_sentiment.3.relevance_score
0.099066
|
feed.28.ticker_sentiment.3.ticker_sentiment_score
-0.318308
|
feed.28.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bearish
|
feed.28.ticker_sentiment.4.ticker
DLTR
|
feed.28.ticker_sentiment.4.relevance_score
0.381463
|
feed.28.ticker_sentiment.4.ticker_sentiment_score
-0.089691
|
feed.28.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.28.ticker_sentiment.5.ticker
MNMD
|
feed.28.ticker_sentiment.5.relevance_score
0.291182
|
feed.28.ticker_sentiment.5.ticker_sentiment_score
0.193328
|
feed.28.ticker_sentiment.5.ticker_sentiment_label
Somewhat-Bullish
|
feed.28.ticker_sentiment.6.ticker
WMT
|
feed.28.ticker_sentiment.6.relevance_score
0.19661
|
feed.28.ticker_sentiment.6.ticker_sentiment_score
0.201257
|
feed.28.ticker_sentiment.6.ticker_sentiment_label
Somewhat-Bullish
|
feed.29.title
This is Just the Beginning of Mind Medicine
|
feed.29.url
https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/
|
feed.29.time_published
20240308T155933
|
feed.29.authors.0
Chris Johnson
|
feed.29.summary
My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
|
feed.29.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png
|
feed.29.source
Money Morning
|
feed.29.category_within_source
RSS
|
feed.29.topics.0.topic
Life Sciences
|
feed.29.source_domain
moneymorning.com
|
feed.29.topics.2.topic
Financial Markets
|
feed.29.topics.1.relevance_score
0.5
|
feed.29.overall_sentiment_score
0.193082
|
feed.29.overall_sentiment_label
Somewhat-Bullish
|
feed.29.ticker_sentiment.0.ticker
LLY
|
feed.29.ticker_sentiment.0.relevance_score
0.087663
|
feed.29.ticker_sentiment.0.ticker_sentiment_score
0.031875
|
feed.29.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.29.ticker_sentiment.1.ticker
ABBV
|
feed.29.ticker_sentiment.1.relevance_score
0.087663
|
feed.29.ticker_sentiment.1.ticker_sentiment_score
0.058676
|
feed.29.ticker_sentiment.2.ticker
CCORF
|
feed.29.topics.0.relevance_score
0.5
|
feed.29.topics.1.topic
Technology
|
feed.29.topics.2.relevance_score
0.723405
|
feed.29.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.29.ticker_sentiment.2.relevance_score
0.043898
|
feed.29.ticker_sentiment.2.ticker_sentiment_score
0.097077
|
feed.29.ticker_sentiment.3.relevance_score
0.379691
|
feed.29.ticker_sentiment.3.ticker_sentiment_score
0.301289
|
feed.29.ticker_sentiment.3.ticker
MNMD
|
feed.29.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.29.ticker_sentiment.4.ticker
PFE
|
feed.29.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.29.ticker_sentiment.4.relevance_score
0.087663
|
feed.29.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.29.ticker_sentiment.4.ticker_sentiment_score
0.058676
|
feed.30.title
MindMed's  ( MNMD )  Anxiety Drug Gets FDA Breakthrough Therapy Tag
|
feed.30.url
https://www.zacks.com/stock/news/2238092/mindmeds-mnmd-anxiety-drug-gets-fda-breakthrough-therapy-tag
|
feed.30.time_published
20240308T154600
|
feed.30.authors.0
Zacks Equity Research
|
feed.30.summary
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
|
feed.30.banner_image
https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg
|
feed.30.source
Zacks Commentary
|
feed.30.topics.0.topic
Earnings
|
feed.30.category_within_source
n/a
|
feed.30.source_domain
www.zacks.com
|
feed.30.topics.0.relevance_score
0.972193
|
feed.30.topics.1.topic
Life Sciences
|
feed.30.topics.1.relevance_score
0.5
|
feed.30.topics.2.topic
Technology
|
feed.30.topics.2.relevance_score
0.5
|
feed.30.overall_sentiment_score
0.183929
|
feed.30.overall_sentiment_label
Somewhat-Bullish
|
feed.30.ticker_sentiment.0.ticker
ADMA
|
feed.30.ticker_sentiment.0.relevance_score
0.401331
|
feed.30.ticker_sentiment.0.ticker_sentiment_score
0.288663
|
feed.30.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.30.ticker_sentiment.1.relevance_score
0.401331
|
feed.30.ticker_sentiment.1.ticker
ANIP
|
feed.30.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.30.ticker_sentiment.1.ticker_sentiment_score
0.345265
|
feed.30.ticker_sentiment.2.ticker
MNMD
|
feed.30.ticker_sentiment.2.relevance_score
0.207571
|
feed.30.ticker_sentiment.2.ticker_sentiment_score
0.048022
|
feed.30.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.30.ticker_sentiment.3.ticker
VNDA
|
feed.30.ticker_sentiment.3.relevance_score
0.401331
|
feed.30.ticker_sentiment.3.ticker_sentiment_score
0.153063
|
feed.31.title
MindMed's  ( MNMD )  Anxiety Drug Gets FDA Breakthrough Therapy Tag
|
feed.31.authors.0
Zacks Equity Research
|
feed.31.summary
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
|
feed.31.banner_image
https://staticx-tuner.zacks.com/images/articles/main/58/608.jpg
|
feed.31.source
Zacks Commentary
|
feed.30.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.31.url
https://www.zacks.com/stock/news/2238092/mindmeds-mnmd-anxiety-drug-gets-fda-breakthrough-therapy-tag
|
feed.31.time_published
20240308T144600
|
feed.31.category_within_source
n/a
|
feed.31.topics.0.topic
Earnings
|
feed.31.topics.0.relevance_score
0.972193
|
feed.31.source_domain
www.zacks.com
|
feed.31.topics.1.topic
Life Sciences
|
feed.31.topics.1.relevance_score
0.5
|
feed.31.topics.2.topic
Technology
|
feed.31.topics.2.relevance_score
0.5
|
feed.31.overall_sentiment_score
0.183929
|
feed.31.overall_sentiment_label
Somewhat-Bullish
|
feed.31.ticker_sentiment.0.ticker
ADMA
|
feed.31.ticker_sentiment.0.relevance_score
0.401331
|
feed.31.ticker_sentiment.0.ticker_sentiment_score
0.288663
|
feed.31.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.31.ticker_sentiment.1.ticker
ANIP
|
feed.31.ticker_sentiment.1.relevance_score
0.401331
|
feed.31.ticker_sentiment.1.ticker_sentiment_score
0.345265
|
feed.31.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.31.ticker_sentiment.2.ticker
MNMD
|
feed.31.ticker_sentiment.2.relevance_score
0.207571
|
feed.31.ticker_sentiment.2.ticker_sentiment_score
0.048022
|
feed.31.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.31.ticker_sentiment.3.ticker
VNDA
|
feed.31.ticker_sentiment.3.relevance_score
0.401331
|
feed.31.ticker_sentiment.3.ticker_sentiment_score
0.153063
|
feed.31.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.32.url
https://www.newswire.ca/news-releases/numinus-wellness-congratulates-mindmed-on-positive-results-from-phase-2b-clinical-trials-of-mm120-for-generalized-anxiety-disorder-833854410.html
|
feed.28.url
https://moneymorning.com/2024/03/13/three-stocks-mindmed-tesla-and-dollar-tree/
|
feed.32.time_published
20240308T120000
|
feed.32.title
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
|
feed.32.authors.0
Numinus Wellness Inc.
|
feed.32.banner_image
https://mma.prnewswire.com/media/2357529/Numinus_Wellness_Inc__Numinus_Wellness_Congratulates_MindMed_on.jpg?p=facebook
|
feed.32.source
Canada Newswire
|
feed.32.category_within_source
n/a
|
feed.32.summary
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for ... Canada ...
|
feed.32.source_domain
www.newswire.ca
|
feed.32.topics.0.topic
Technology
|
feed.32.topics.0.relevance_score
1.0
|
feed.32.overall_sentiment_score
0.178278
|
feed.32.overall_sentiment_label
Somewhat-Bullish
|
feed.32.ticker_sentiment.0.ticker
MNMD
|
feed.32.ticker_sentiment.0.relevance_score
0.110973
|
feed.32.ticker_sentiment.0.ticker_sentiment_score
0.169483
|
feed.32.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.33.title
This is Just the Beginning of Mind Medicine
|
feed.33.url
https://moneymorning.com/2024/03/08/this-is-just-the-beginning-of-mind-medicine/
|
feed.33.time_published
20240308T080000
|
feed.33.authors.0
Chris Johnson
|
feed.33.banner_image
https://moneymorning.com/wp-content/blogs.dir/1/files/2024/03/mnmd.png
|
feed.33.source
Money Morning
|
feed.33.summary
My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
|
feed.33.category_within_source
GoogleRSS
|
feed.33.topics.0.topic
Life Sciences
|
feed.33.topics.0.relevance_score
0.5
|
feed.33.source_domain
moneymorning.com
|
feed.33.topics.1.topic
Technology
|
feed.33.topics.2.topic
Financial Markets
|
feed.33.topics.1.relevance_score
0.5
|
feed.33.topics.2.relevance_score
0.723405
|
feed.33.overall_sentiment_score
0.193082
|
feed.33.overall_sentiment_label
Somewhat-Bullish
|
feed.33.ticker_sentiment.0.ticker
LLY
|
feed.33.ticker_sentiment.0.relevance_score
0.087663
|
feed.33.ticker_sentiment.0.ticker_sentiment_score
0.031875
|
feed.33.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.33.ticker_sentiment.1.ticker
ABBV
|
feed.33.ticker_sentiment.1.relevance_score
0.087663
|
feed.33.ticker_sentiment.1.ticker_sentiment_score
0.058676
|
feed.33.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.33.ticker_sentiment.2.ticker
CCORF
|
feed.33.ticker_sentiment.2.relevance_score
0.043898
|
feed.33.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.33.ticker_sentiment.2.ticker_sentiment_score
0.097077
|
feed.33.ticker_sentiment.3.ticker
MNMD
|
feed.33.ticker_sentiment.3.relevance_score
0.379691
|
feed.33.ticker_sentiment.3.ticker_sentiment_score
0.301289
|
feed.33.ticker_sentiment.4.ticker
PFE
|
feed.33.ticker_sentiment.4.relevance_score
0.087663
|
feed.33.ticker_sentiment.4.ticker_sentiment_score
0.058676
|
feed.33.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.34.title
S&P 500 Gains 1%; Kroger Earnings Top Views - Brera Holdings  ( NASDAQ:BREA ) , Avid Bioservices  ( NASDAQ:CDMO ) 
|
feed.34.url
https://www.benzinga.com/news/earnings/24/03/37544012/s-p-500-gains-1-kroger-earnings-top-views
|
feed.34.time_published
20240307T193151
|
feed.34.authors.0
Avi Kapoor
|
feed.34.summary
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 250 points on Thursday. The Dow traded up 0.34% to 38,793.79 while the NASDAQ rose 1.63% to 16,292.61. The S&P 500 also rose, gaining, 1.06% to 5,158.91. Communication services shares jumped by 1.9% on ...
|
feed.34.banner_image
https://cdn.benzinga.com/files/images/story/2024/03/07/image41.jpg?width=1200&height=800&fit=crop
|
feed.34.source
Benzinga
|
feed.34.category_within_source
Trading
|
feed.34.source_domain
www.benzinga.com
|
feed.34.topics.0.topic
Life Sciences
|
feed.34.topics.0.relevance_score
0.25
|
feed.34.topics.1.topic
Retail & Wholesale
|
feed.34.topics.1.relevance_score
0.25
|
feed.34.topics.2.topic
Financial Markets
|
feed.34.topics.2.relevance_score
0.684621
|
feed.34.topics.3.topic
Manufacturing
|
feed.34.topics.3.relevance_score
0.25
|
feed.34.topics.4.topic
Earnings
|
feed.34.topics.4.relevance_score
0.818451
|
feed.34.topics.5.topic
Technology
|
feed.34.topics.5.relevance_score
0.25
|
feed.34.overall_sentiment_score
0.092961
|
feed.34.overall_sentiment_label
Neutral
|
feed.34.ticker_sentiment.0.ticker
MEI
|
feed.34.ticker_sentiment.0.relevance_score
0.135347
|
feed.34.ticker_sentiment.0.ticker_sentiment_score
-0.055998
|
feed.34.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.34.ticker_sentiment.1.ticker
VSCO
|
feed.34.ticker_sentiment.1.relevance_score
0.135347
|
feed.34.ticker_sentiment.1.ticker_sentiment_score
0.216391
|
feed.34.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.34.ticker_sentiment.2.ticker
BREA
|
feed.34.ticker_sentiment.2.relevance_score
0.135347
|
feed.34.ticker_sentiment.2.ticker_sentiment_score
0.200702
|
feed.34.ticker_sentiment.2.ticker_sentiment_label
Somewhat-Bullish
|
feed.34.ticker_sentiment.3.ticker
LYT
|
feed.34.ticker_sentiment.3.relevance_score
0.135347
|
feed.34.ticker_sentiment.3.ticker_sentiment_score
0.013977
|
feed.34.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.34.ticker_sentiment.4.ticker
KR
|
feed.34.ticker_sentiment.4.relevance_score
0.201803
|
feed.34.ticker_sentiment.4.ticker_sentiment_score
0.138787
|
feed.34.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.34.ticker_sentiment.5.ticker
CDMO
|
feed.34.ticker_sentiment.5.relevance_score
0.135347
|
feed.34.ticker_sentiment.5.ticker_sentiment_score
0.020927
|
feed.34.ticker_sentiment.6.ticker
MNMD
|
feed.34.ticker_sentiment.6.ticker_sentiment_score
0.108521
|
feed.34.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.34.ticker_sentiment.6.relevance_score
0.135347
|
feed.34.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.35.title
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials - Compass Pathways  ( NASDAQ:CMPS ) , Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.35.url
https://www.benzinga.com/general/biotech/24/03/37542756/mindmed-receives-fda-breakthrough-therapy-designation-for-lsd-as-anxiety-treatment-shares-positiv
|
feed.35.time_published
20240307T183502
|
feed.35.authors.0
Lara Goldstein
|
feed.35.summary
Mind Medicine ( MindMed ) MNMD announced that the FDA has granted the "breakthrough therapy" designation to its MM120 ( lysergide d-tartrate ) program for the treatment of Generalized Anxiety Disorder ( GAD ) .
|
feed.35.banner_image
https://cdn.benzinga.com/files/images/story/2024/scott-graham-OQMZwNd3ThU-unsplash.jpeg?width=1200&height=800&fit=crop
|
feed.35.source
Benzinga
|
feed.35.category_within_source
News
|
feed.35.source_domain
www.benzinga.com
|
feed.35.topics.0.topic
Life Sciences
|
feed.35.topics.0.relevance_score
0.5
|
feed.35.topics.1.topic
Technology
|
feed.35.topics.1.relevance_score
0.5
|
feed.35.overall_sentiment_score
0.09054
|
feed.35.overall_sentiment_label
Neutral
|
feed.35.ticker_sentiment.0.ticker
MNMD
|
feed.35.ticker_sentiment.0.relevance_score
0.126784
|
feed.35.ticker_sentiment.0.ticker_sentiment_score
0.050765
|
feed.35.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.35.ticker_sentiment.1.ticker
CMPS
|
feed.35.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.36.title
What's Going On With MindMed Stock Thursday? - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.35.ticker_sentiment.1.relevance_score
0.126784
|
feed.35.ticker_sentiment.1.ticker_sentiment_score
0.031483
|
feed.36.url
https://www.benzinga.com/news/24/03/37536299/whats-going-on-with-mindmed-stock-thursday
|
feed.36.time_published
20240307T145441
|
feed.36.authors.0
Adam Eckert
|
feed.36.summary
Mind Medicine Inc MNMD shares are trading higher Thursday after the company received FDA breakthrough therapy designation and announced positive study data. What Happened: MindMed announced that the FDA has granted breakthrough designation to its MM120 ( lysergide d-tartrate ) program for the ...
|
feed.36.banner_image
https://cdn.benzinga.com/files/images/story/2024/stock-chart-1863880-1920-60_16.jpeg?width=1200&height=800&fit=crop
|
feed.36.source
Benzinga
|
feed.36.category_within_source
News
|
feed.36.source_domain
www.benzinga.com
|
feed.36.topics.0.topic
IPO
|
feed.36.topics.0.relevance_score
0.158519
|
feed.36.topics.1.topic
Technology
|
feed.36.topics.1.relevance_score
1.0
|
feed.36.topics.2.topic
Financial Markets
|
feed.36.topics.2.relevance_score
0.161647
|
feed.36.overall_sentiment_score
0.210352
|
feed.36.overall_sentiment_label
Somewhat-Bullish
|
feed.36.ticker_sentiment.0.ticker_sentiment_score
0.389716
|
feed.36.ticker_sentiment.0.ticker
MNMD
|
feed.36.ticker_sentiment.0.relevance_score
0.330286
|
feed.36.ticker_sentiment.0.ticker_sentiment_label
Bullish
|
feed.37.title
Single dose of LSD provides immediate, lasting anxiety relief, study says
|
feed.37.url
https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html
|
feed.37.time_published
20240307T120000
|
feed.37.authors.0
Sandee LaMotte
|
feed.37.summary
Single dose of LSD provides immediate and lasting relief from anxiety, study says ...
|
feed.37.banner_image
https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-1348113243.jpg?q=w_1110,c_fill
|
feed.37.source
CNN
|
feed.37.category_within_source
Markets
|
feed.37.source_domain
www.cnn.com
|
feed.37.topics.0.topic
Technology
|
feed.37.topics.0.relevance_score
1.0
|
feed.37.overall_sentiment_score
-0.071129
|
feed.37.overall_sentiment_label
Neutral
|
feed.37.ticker_sentiment.0.ticker
MNMD
|
feed.37.ticker_sentiment.0.relevance_score
0.032469
|
feed.37.ticker_sentiment.0.ticker_sentiment_score
0.203571
|
feed.37.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.37.ticker_sentiment.1.ticker
WSFL
|
feed.37.ticker_sentiment.1.relevance_score
0.032469
|
feed.37.ticker_sentiment.1.ticker_sentiment_score
-0.165819
|
feed.37.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bearish
|
feed.38.title
Elon Musk Says, 'If Drugs Helped My Productivity I'd Take Them' - This Psychedelic Bio-Tech Company Hopes To Help Build That Future - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.38.url
https://www.benzinga.com/general/24/02/36936818/elon-musk-says-if-drugs-helped-my-productivity-id-take-them-this-psychedelic-bio-tech-company-hopes
|
feed.38.time_published
20240205T170400
|
feed.38.authors.0
Caleb Naysmith
|
feed.38.banner_image
https://cdn.benzinga.com/files/images/story/2024/Elon-Musk-xAI_3.jpeg?width=1200&height=800&fit=crop
|
feed.38.source
Benzinga
|
feed.38.category_within_source
General
|
feed.38.summary
Never a stranger to controversy, Tesla Inc. CEO Elon Musk caught people's attention again when he said, "If drugs actually helped improve my net productivity over time, I would definitely take them!"
|
feed.38.source_domain
www.benzinga.com
|
feed.38.topics.0.topic
Technology
|
feed.38.topics.0.relevance_score
0.5
|
feed.38.topics.1.topic
Financial Markets
|
feed.38.topics.1.relevance_score
0.316726
|
feed.38.topics.2.topic
Manufacturing
|
feed.38.topics.2.relevance_score
0.5
|
feed.38.overall_sentiment_score
0.048699
|
feed.38.overall_sentiment_label
Neutral
|
feed.38.ticker_sentiment.0.ticker
MNMD
|
feed.38.ticker_sentiment.0.relevance_score
0.214304
|
feed.38.ticker_sentiment.1.ticker
TSLA
|
feed.33.ticker_sentiment.3.ticker_sentiment_label
Somewhat-Bullish
|
feed.38.ticker_sentiment.0.ticker_sentiment_score
0.060113
|
feed.38.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.38.ticker_sentiment.1.relevance_score
0.072217
|
feed.38.ticker_sentiment.1.ticker_sentiment_score
0.175157
|
feed.38.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.39.title
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) 
|
feed.39.time_published
20240127T150018
|
feed.39.url
https://www.benzinga.com/markets/cannabis/24/01/36814962/psyched-suggestibility-and-psychedelics-effects-eus-7m-research-fund-australias-treatment-delive
|
feed.39.authors.0
Lara Goldstein
|
feed.39.summary
A new study led by BalÃ¡zs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy.
|
feed.39.banner_image
https://cdn.benzinga.com/files/images/story/2024/Psyched.png?width=1200&height=800&fit=crop
|
feed.39.source
Benzinga
|
feed.39.category_within_source
Markets
|
feed.39.source_domain
www.benzinga.com
|
feed.39.topics.0.topic
Life Sciences
|
feed.39.topics.0.relevance_score
0.333333
|
feed.39.topics.1.topic
Financial Markets
|
feed.39.topics.2.relevance_score
0.333333
|
feed.39.topics.2.topic
Manufacturing
|
feed.39.topics.3.topic
Technology
|
feed.39.overall_sentiment_label
Neutral
|
feed.39.topics.3.relevance_score
0.333333
|
feed.39.overall_sentiment_score
0.071122
|
feed.39.ticker_sentiment.0.relevance_score
0.09239
|
feed.39.ticker_sentiment.0.ticker
DRUG
|
feed.39.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.39.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.1.ticker
IXHL
|
feed.39.ticker_sentiment.1.relevance_score
0.183546
|
feed.39.ticker_sentiment.1.ticker_sentiment_score
0.18278
|
feed.39.ticker_sentiment.1.ticker_sentiment_label
Somewhat-Bullish
|
feed.39.ticker_sentiment.2.ticker
CMPS
|
feed.39.ticker_sentiment.2.relevance_score
0.138198
|
feed.39.ticker_sentiment.2.ticker_sentiment_score
-0.062971
|
feed.39.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.3.ticker
ENVB
|
feed.39.topics.1.relevance_score
0.87644
|
feed.39.ticker_sentiment.3.relevance_score
0.09239
|
feed.39.ticker_sentiment.3.ticker_sentiment_score
-0.114703
|
feed.39.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.4.ticker
MNMD
|
feed.39.ticker_sentiment.4.relevance_score
0.138198
|
feed.39.ticker_sentiment.4.ticker_sentiment_score
0.0
|
feed.39.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.5.ticker
CMND
|
feed.39.ticker_sentiment.5.ticker_sentiment_score
0.0
|
feed.39.ticker_sentiment.5.relevance_score
0.09239
|
feed.39.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.6.ticker
SEEL
|
feed.39.ticker_sentiment.6.relevance_score
0.09239
|
feed.39.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.39.ticker_sentiment.7.ticker
SILO
|
feed.39.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.39.ticker_sentiment.7.relevance_score
0.09239
|
feed.39.ticker_sentiment.7.ticker_sentiment_score
0.0
|
feed.39.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.40.title
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) 
|
feed.40.url
https://www.benzinga.com/markets/cannabis/24/01/36618728/psyched-100m-for-mdma-therapy-va-funds-2024-watchlist-reform-updates-and-more
|
feed.40.authors.0
Lara Goldstein
|
feed.40.time_published
20240112T215540
|
feed.40.summary
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies ( MAPS ) , MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale.
|
feed.40.source
Benzinga
|
feed.40.category_within_source
Markets
|
feed.40.banner_image
https://cdn.benzinga.com/files/images/story/2024/01/12/psyched.png?width=1200&height=800&fit=crop
|
feed.40.source_domain
www.benzinga.com
|
feed.40.topics.0.topic
Life Sciences
|
feed.40.topics.0.relevance_score
0.333333
|
feed.40.topics.1.topic
Financial Markets
|
feed.40.topics.1.relevance_score
0.87644
|
feed.40.topics.2.topic
Manufacturing
|
feed.40.topics.2.relevance_score
0.333333
|
feed.40.topics.3.topic
Technology
|
feed.40.topics.3.relevance_score
0.333333
|
feed.40.overall_sentiment_score
0.192357
|
feed.40.ticker_sentiment.0.relevance_score
0.095899
|
feed.40.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.40.ticker_sentiment.0.ticker
DRUG
|
feed.40.overall_sentiment_label
Somewhat-Bullish
|
feed.40.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.1.ticker
IXHL
|
feed.40.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.1.relevance_score
0.095899
|
feed.40.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.40.ticker_sentiment.2.ticker
CMPS
|
feed.40.ticker_sentiment.2.relevance_score
0.095899
|
feed.40.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.3.relevance_score
0.095899
|
feed.40.ticker_sentiment.2.ticker_sentiment_score
-0.115703
|
feed.40.ticker_sentiment.3.ticker
ENVB
|
feed.40.ticker_sentiment.3.ticker_sentiment_score
0.0
|
feed.40.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.4.ticker
MNMD
|
feed.40.ticker_sentiment.4.relevance_score
0.143415
|
feed.40.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.5.ticker
CMND
|
feed.40.ticker_sentiment.4.ticker_sentiment_score
-0.109978
|
feed.40.ticker_sentiment.5.relevance_score
0.095899
|
feed.40.ticker_sentiment.5.ticker_sentiment_score
-0.131577
|
feed.40.ticker_sentiment.6.ticker
SEEL
|
feed.40.ticker_sentiment.6.relevance_score
0.095899
|
feed.40.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.40.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.40.ticker_sentiment.7.ticker
SILO
|
feed.40.ticker_sentiment.7.ticker_sentiment_score
0.136873
|
feed.40.ticker_sentiment.7.relevance_score
0.095899
|
feed.40.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.41.title
MindMed's 2024 Plans: Anxiety Treatment Stands, LSD Microdosing For ADHD Will Be Discontinued - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.41.url
https://www.benzinga.com/markets/cannabis/24/01/36595035/mindmeds-2024-plans-anxiety-treatment-stands-lsd-microdosing-for-adhd-will-be-discontinued
|
feed.41.summary
Earlier this week, biopharma company Mind Medicine ( MindMed ) MNMD released latest clinical trial results on repeated sub-perceptual doses of its LSD compound, MM-120, in adults with ADHD. The company also provided a corporate update and outlook for 2024. MM-120 is Mind Medicine's lead drug ...
|
feed.41.time_published
20240111T154313
|
feed.41.authors.0
Lara Goldstein
|
feed.41.source
Benzinga
|
feed.41.category_within_source
Markets
|
feed.41.banner_image
https://cdn.benzinga.com/files/images/story/2024/01/11/lsd_doctor_romolo_tavani_and_sendo_serra_by_shutterstock.jpg?width=1200&height=800&fit=crop
|
feed.41.source_domain
www.benzinga.com
|
feed.41.topics.0.topic
Technology
|
feed.41.topics.0.relevance_score
1.0
|
feed.41.topics.1.topic
Financial Markets
|
feed.41.topics.1.relevance_score
0.108179
|
feed.41.overall_sentiment_label
Somewhat-Bullish
|
feed.41.overall_sentiment_score
0.15305
|
feed.41.ticker_sentiment.0.ticker
MNMD
|
feed.41.ticker_sentiment.0.relevance_score
0.117486
|
feed.41.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.41.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.41.ticker_sentiment.1.ticker
SSTK
|
feed.41.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.41.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.41.ticker_sentiment.1.relevance_score
0.058903
|
feed.42.title
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Clearmind Medicine  ( NASDAQ:CMND ) 
|
feed.42.url
https://www.benzinga.com/general/biotech/24/01/36518391/psyched-ibogaine-for-tbi-kentucky-initiative-stalled-dea-quotas-insurance-codes-atais-50m-and-mor
|
feed.42.authors.0
Lara Goldstein
|
feed.42.time_published
20240107T173634
|
feed.42.banner_image
https://cdn.benzinga.com/files/images/story/2024/01/05/psyched.png?width=1200&height=800&fit=crop
|
feed.42.summary
Results of a first-in-class clinical trial on ibogaine-magnesium therapy for Special Operations Veterans ( SOV ) with repeated blast exposure have been published in the journal Nature. Although preliminary, outcomes have long been awaited as they provide evidence of ibogaine's neuro-restorative ...
|
feed.42.source
Benzinga
|
feed.42.category_within_source
Markets
|
feed.42.source_domain
www.benzinga.com
|
feed.42.topics.0.topic
Life Sciences
|
feed.42.topics.0.relevance_score
0.333333
|
feed.42.topics.1.topic
Financial Markets
|
feed.42.topics.1.relevance_score
0.87644
|
feed.42.topics.2.topic
Manufacturing
|
feed.42.topics.3.topic
Technology
|
feed.42.topics.3.relevance_score
0.333333
|
feed.42.topics.2.relevance_score
0.333333
|
feed.42.overall_sentiment_score
0.16017
|
feed.42.overall_sentiment_label
Somewhat-Bullish
|
feed.42.ticker_sentiment.0.ticker
DRUG
|
feed.42.ticker_sentiment.0.relevance_score
0.104683
|
feed.42.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.1.ticker
IXHL
|
feed.42.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.2.relevance_score
0.104683
|
feed.42.ticker_sentiment.1.relevance_score
0.104683
|
feed.42.ticker_sentiment.2.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.2.ticker
CMPS
|
feed.42.ticker_sentiment.3.ticker
ENVB
|
feed.42.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.3.relevance_score
0.104683
|
feed.42.ticker_sentiment.3.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.4.ticker
MNMD
|
feed.42.ticker_sentiment.4.relevance_score
0.104683
|
feed.42.ticker_sentiment.4.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.5.ticker
CMND
|
feed.42.ticker_sentiment.5.relevance_score
0.104683
|
feed.42.ticker_sentiment.5.ticker_sentiment_score
-0.118564
|
feed.42.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.6.ticker
SEEL
|
feed.42.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.42.ticker_sentiment.6.relevance_score
0.104683
|
feed.42.ticker_sentiment.6.ticker_sentiment_score
-0.110976
|
feed.42.ticker_sentiment.7.ticker_sentiment_score
0.0
|
feed.42.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.43.title
Psychedelic Stock Gainers And Losers From January 1, 2024 - Compass Pathways  ( NASDAQ:CMPS ) , ATAI Life Sciences  ( NASDAQ:ATAI ) 
|
feed.43.url
https://www.benzinga.com/markets/cannabis/24/01/36445128/psychedelic-stock-gainers-and-losers-from-january-1-2024
|
feed.43.time_published
20240101T213005
|
feed.43.authors.0
Benzinga Insights
|
feed.43.summary
Cybin CYBN shares closed up 1.49% at $0.41 ATAI Life Sciences ATAI shares closed down 5.37% at $1.41 Mind Medicine MNMD shares closed down 5.26% at $3.60 Compass Pathways CMPS shares closed down 2.98% at $8.80 GH Research GHRS shares closed down 1.62% at $5.45
|
feed.43.banner_image
https://cdn.benzinga.com/files/images/story/2023/psychedelic_image.png?width=1200&height=800&fit=crop
|
feed.43.source
Benzinga
|
feed.43.category_within_source
Markets
|
feed.43.source_domain
www.benzinga.com
|
feed.43.topics.0.topic
Life Sciences
|
feed.43.topics.0.relevance_score
0.5
|
feed.43.topics.1.topic
Technology
|
feed.43.topics.1.relevance_score
0.5
|
feed.43.topics.2.topic
Financial Markets
|
feed.42.ticker_sentiment.7.relevance_score
0.104683
|
feed.43.topics.2.relevance_score
0.108179
|
feed.43.overall_sentiment_score
0.353099
|
feed.43.overall_sentiment_label
Bullish
|
feed.43.ticker_sentiment.0.ticker
MNMD
|
feed.43.ticker_sentiment.0.relevance_score
0.447528
|
feed.43.ticker_sentiment.0.ticker_sentiment_label
Bullish
|
feed.43.ticker_sentiment.1.ticker
CMPS
|
feed.43.ticker_sentiment.0.ticker_sentiment_score
0.607545
|
feed.43.ticker_sentiment.1.relevance_score
0.447528
|
feed.43.ticker_sentiment.1.ticker_sentiment_score
0.607545
|
feed.43.ticker_sentiment.1.ticker_sentiment_label
Bullish
|
feed.44.title
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More - Awakn Life Sciences  ( OTC:AWKNF ) , ATAI Life Sciences  ( NASDAQ:ATAI ) 
|
feed.44.url
https://www.benzinga.com/markets/cannabis/23/12/36390332/psyched-biden-approves-psychedelics-trials-rfk-australias-first-legal-dedicated-clinic-more
|
feed.44.time_published
20231227T150926
|
feed.44.authors.0
Lara Goldstein
|
feed.44.summary
President Biden signed into law the 2024 National Defense Authorization Act ( NDAA ) , large-scale legislation that also contains a mandate to fund clinical trials with psychedelics for active service members.
|
feed.44.banner_image
https://cdn.benzinga.com/files/images/story/2023/12/26/psyched.png?width=1200&height=800&fit=crop
|
feed.44.source
Benzinga
|
feed.44.category_within_source
Markets
|
feed.44.source_domain
www.benzinga.com
|
feed.44.topics.0.topic
Life Sciences
|
feed.44.topics.1.topic
Financial Markets
|
feed.44.topics.0.relevance_score
0.25
|
feed.44.topics.1.relevance_score
0.796627
|
feed.44.topics.2.topic
Manufacturing
|
feed.44.topics.2.relevance_score
0.25
|
feed.44.topics.3.topic
Real Estate & Construction
|
feed.44.topics.3.relevance_score
0.25
|
feed.44.topics.4.topic
Technology
|
feed.44.topics.4.relevance_score
0.25
|
feed.44.overall_sentiment_score
0.129429
|
feed.44.overall_sentiment_label
Neutral
|
feed.44.ticker_sentiment.0.ticker
DRUG
|
feed.44.ticker_sentiment.0.relevance_score
0.059194
|
feed.44.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.1.ticker
IXHL
|
feed.44.ticker_sentiment.1.relevance_score
0.118064
|
feed.44.ticker_sentiment.1.ticker_sentiment_score
0.070537
|
feed.44.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.2.ticker
CMPS
|
feed.42.ticker_sentiment.7.ticker
SILO
|
feed.44.ticker_sentiment.2.relevance_score
0.118064
|
feed.44.ticker_sentiment.2.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.3.ticker
ENVB
|
feed.44.ticker_sentiment.3.ticker_sentiment_score
-0.102998
|
feed.44.ticker_sentiment.3.relevance_score
0.059194
|
feed.44.ticker_sentiment.4.relevance_score
0.059194
|
feed.44.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.4.ticker
HUGE
|
feed.44.ticker_sentiment.4.ticker_sentiment_score
0.462851
|
feed.44.ticker_sentiment.4.ticker_sentiment_label
Bullish
|
feed.44.ticker_sentiment.5.ticker
JAQC
|
feed.44.ticker_sentiment.5.relevance_score
0.029618
|
feed.44.ticker_sentiment.5.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.6.relevance_score
0.059194
|
feed.44.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.6.ticker
MNMD
|
feed.44.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.7.ticker
CMND
|
feed.44.ticker_sentiment.7.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.8.ticker
SEEL
|
feed.44.ticker_sentiment.8.relevance_score
0.059194
|
feed.44.ticker_sentiment.8.ticker_sentiment_label
Neutral
|
feed.44.ticker_sentiment.8.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.9.ticker
SILO
|
feed.44.ticker_sentiment.9.relevance_score
0.059194
|
feed.44.ticker_sentiment.9.ticker_sentiment_score
0.0
|
feed.44.ticker_sentiment.9.ticker_sentiment_label
Neutral
|
feed.45.title
What Makes Mind Medicine  ( MindMed )  Inc.  ( MNMD )  a New Buy Stock
|
feed.45.url
https://www.zacks.com/stock/news/2200679/what-makes-mind-medicine-mindmed-inc-mnmd-a-new-buy-stock
|
feed.45.time_published
20231220T170005
|
feed.45.authors.0
Zacks Equity Research
|
feed.45.summary
Mind Medicine (MindMed) Inc. (MNMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
|
feed.45.banner_image
https://staticx-tuner.zacks.com/images/default_article_images/default237.jpg
|
feed.45.source
Zacks Commentary
|
feed.45.category_within_source
n/a
|
feed.45.source_domain
www.zacks.com
|
feed.45.topics.0.topic
Earnings
|
feed.45.topics.0.relevance_score
0.997845
|
feed.45.topics.1.topic
Technology
|
feed.45.topics.1.relevance_score
1.0
|
feed.45.topics.2.relevance_score
0.658903
|
feed.45.overall_sentiment_score
0.298698
|
feed.45.topics.2.topic
Financial Markets
|
feed.45.overall_sentiment_label
Somewhat-Bullish
|
feed.45.ticker_sentiment.0.ticker
MNMD
|
feed.45.ticker_sentiment.0.relevance_score
0.355588
|
feed.45.ticker_sentiment.0.ticker_sentiment_label
Somewhat-Bullish
|
feed.45.ticker_sentiment.0.ticker_sentiment_score
0.295151
|
feed.46.title
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More - Bright Minds Biosciences  ( NASDAQ:DRUG ) , Incannex Healthcare  ( NASDAQ:IXHL ) , Compass Pathways  ( NASDAQ:CMPS ) , GH Research  ( NASDAQ:GHRS ) 
|
feed.46.url
https://www.benzinga.com/markets/cannabis/23/12/36284691/psyched-bidens-big-decision-on-psychedelics-therapy-lsd-anxiety-results-matthew-perry-autopsy-an
|
feed.46.time_published
20231218T172139
|
feed.46.authors.0
Lara Goldstein
|
feed.46.summary
President Joe Biden received the final version of a large-scale defense bill providing funding for psychedelics clinical trials for military service members.
|
feed.46.banner_image
https://cdn.benzinga.com/files/images/story/2023/12/18/psyched.png?width=1200&height=800&fit=crop
|
feed.46.category_within_source
Markets
|
feed.46.source_domain
www.benzinga.com
|
feed.46.topics.0.topic
Life Sciences
|
feed.46.topics.0.relevance_score
0.333333
|
feed.46.topics.1.relevance_score
0.87644
|
feed.44.ticker_sentiment.7.relevance_score
0.059194
|
feed.46.topics.2.topic
Manufacturing
|
feed.46.topics.1.topic
Financial Markets
|
feed.46.topics.3.topic
Technology
|
feed.46.topics.3.relevance_score
0.333333
|
feed.46.overall_sentiment_score
0.057439
|
feed.46.topics.2.relevance_score
0.333333
|
feed.46.overall_sentiment_label
Neutral
|
feed.46.ticker_sentiment.0.relevance_score
0.079
|
feed.46.ticker_sentiment.0.ticker
DRUG
|
feed.46.ticker_sentiment.0.ticker_sentiment_score
0.0
|
feed.46.source
Benzinga
|
feed.46.ticker_sentiment.1.ticker
IXHL
|
feed.46.ticker_sentiment.1.relevance_score
0.079
|
feed.46.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.1.ticker_sentiment_score
0.053417
|
feed.46.ticker_sentiment.2.ticker
CMPS
|
feed.46.ticker_sentiment.2.ticker_sentiment_score
0.0
|
feed.46.ticker_sentiment.2.relevance_score
0.079
|
feed.46.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.3.relevance_score
0.079
|
feed.46.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.3.ticker
ENVB
|
feed.46.ticker_sentiment.3.ticker_sentiment_score
0.0
|
feed.46.ticker_sentiment.4.ticker
MNMD
|
feed.46.ticker_sentiment.4.relevance_score
0.157227
|
feed.46.ticker_sentiment.4.ticker_sentiment_score
-0.020643
|
feed.46.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.5.relevance_score
0.079
|
feed.46.ticker_sentiment.5.ticker_sentiment_score
0.0
|
feed.46.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.5.ticker
CMND
|
feed.46.ticker_sentiment.6.ticker
SEEL
|
feed.46.ticker_sentiment.6.relevance_score
0.079
|
feed.46.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.46.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.46.ticker_sentiment.7.ticker
SILO
|
feed.46.ticker_sentiment.7.relevance_score
0.079
|
feed.46.ticker_sentiment.7.ticker_sentiment_score
0.0
|
feed.46.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.47.title
Groundbreaking Study: LSD Tartrate Reduces Anxiety Effectively, Says MindMed - Mind Medicine  ( NASDAQ:MNMD ) 
|
feed.47.url
https://www.benzinga.com/markets/cannabis/23/12/36244224/groundbreaking-study-lsd-tartrate-reduces-anxiety-effectively-says-mindmed
|
feed.47.time_published
20231214T192633
|
feed.47.authors.0
Lara Goldstein
|
feed.47.summary
Clinical-stage psychedelics biotech Mind Medicine ( MindMed ) MNMD has published new positive topline results from its Phase 2b study on a single dose of MM-120 ( LSD tartrate, ) with no additional therapeutic intervention, in Generalized Anxiety Disorder ( GAD. )
|
feed.47.banner_image
https://cdn.benzinga.com/files/images/story/2023/12/14/lsd_anxietykat_smith_on_pexels_and_ju_on_wikipedia.jpg?width=1200&height=800&fit=crop
|
feed.47.category_within_source
News
|
feed.47.source
Benzinga
|
feed.47.source_domain
www.benzinga.com
|
feed.47.topics.0.topic
Technology
|
feed.47.topics.0.relevance_score
1.0
|
feed.47.topics.1.topic
Financial Markets
|
feed.47.topics.1.relevance_score
0.108179
|
feed.47.overall_sentiment_score
0.026694
|
feed.47.overall_sentiment_label
Neutral
|
feed.47.ticker_sentiment.0.ticker
MNMD
|
feed.47.ticker_sentiment.0.relevance_score
0.118354
|
feed.47.ticker_sentiment.0.ticker_sentiment_score
-0.076229
|
feed.47.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.47.ticker_sentiment.1.ticker
DSSMY
|
feed.47.ticker_sentiment.1.relevance_score
0.059341
|
feed.47.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.47.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.48.title
MindMed's stock boosted by positive data in trial of LSD as treatment for anxiety disorder
|
feed.48.url
https://www.marketwatch.com/story/mindmed-announces-positive-results-in-trial-of-lsd-as-a-treatment-for-generalized-anxiety-disorder-d0cd2ba2
|
feed.48.time_published
20231214T173900
|
feed.48.authors.0
Ciara Linnane
|
feed.48.summary
Mind Medicine Inc.' stock surged 6.5% Thursday, after the company said a Phase 2 trial testing LSD as a treatment for generalized anxiety disorder met its main goal, showing a statistically significant improvement in scores by week four compared to placebo.
|
feed.48.banner_image
https://images.mktw.net/im-850238/social
|
feed.48.source
MarketWatch
|
feed.48.category_within_source
Top Stories
|
feed.48.source_domain
www.marketwatch.com
|
feed.46.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.48.topics.0.topic
Life Sciences
|
feed.48.topics.0.relevance_score
0.5
|
feed.48.topics.1.topic
Technology
|
feed.48.topics.2.topic
Financial Markets
|
feed.48.topics.2.relevance_score
0.161647
|
feed.48.overall_sentiment_score
0.111456
|
feed.48.topics.1.relevance_score
0.5
|
feed.48.overall_sentiment_label
Neutral
|
feed.48.ticker_sentiment.0.ticker
MNMD
|
feed.48.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.48.ticker_sentiment.0.ticker_sentiment_score
-0.113339
|
feed.48.ticker_sentiment.1.relevance_score
0.182506
|
feed.48.ticker_sentiment.1.ticker
CMPS
|
feed.48.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.49.title
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More - ATAI Life Sciences  ( NASDAQ:ATAI ) , Braxia Scientific  ( OTC:BRAXF ) 
|
feed.48.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.48.ticker_sentiment.0.relevance_score
0.182506
|
feed.49.url
https://www.benzinga.com/markets/cannabis/23/12/36167186/psyched-john-lennon-remembered-clinical-trials-for-service-members-chrissy-teigen-jon-feliciano-
|
feed.49.time_published
20231211T154327
|
feed.49.authors.0
Lara Goldstein
|
feed.49.banner_image
https://cdn.benzinga.com/files/images/story/2023/12/09/psyched.png?width=1200&height=800&fit=crop
|
feed.49.source
Benzinga
|
feed.49.category_within_source
Markets
|
feed.49.topics.0.topic
Life Sciences
|
feed.49.source_domain
www.benzinga.com
|
feed.49.summary
The world seemed to come to a momentary halt on December 8, 1980, when news that John Lennon was shot and killed as he approached his apartment building in New York City came out. Lennon's untimely death sent shockwaves around the world. His contributions to music, activism and peace continue to ...
|
feed.49.topics.0.relevance_score
0.333333
|
feed.49.topics.1.relevance_score
0.796627
|
feed.49.topics.1.topic
Financial Markets
|
feed.49.topics.2.relevance_score
0.333333
|
feed.49.topics.2.topic
Manufacturing
|
feed.49.topics.3.topic
Technology
|
feed.49.topics.3.relevance_score
0.333333
|
feed.49.overall_sentiment_score
0.090539
|
feed.49.overall_sentiment_label
Neutral
|
feed.49.ticker_sentiment.0.ticker
DRUG
|
feed.49.ticker_sentiment.0.ticker_sentiment_score
0.142596
|
feed.49.ticker_sentiment.0.relevance_score
0.087824
|
feed.49.ticker_sentiment.0.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.1.relevance_score
0.087824
|
feed.49.ticker_sentiment.1.ticker_sentiment_score
0.0
|
feed.49.ticker_sentiment.1.ticker
IXHL
|
feed.49.ticker_sentiment.2.ticker
CMPS
|
feed.49.ticker_sentiment.2.ticker_sentiment_score
0.004381
|
feed.49.ticker_sentiment.1.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.2.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.3.relevance_score
0.087824
|
feed.49.ticker_sentiment.2.relevance_score
0.174587
|
feed.49.ticker_sentiment.3.ticker
ENVB
|
feed.49.ticker_sentiment.3.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.4.relevance_score
0.087824
|
feed.49.ticker_sentiment.4.ticker_sentiment_score
0.0
|
feed.49.ticker_sentiment.4.ticker
MNMD
|
feed.49.ticker_sentiment.4.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.3.ticker_sentiment_score
-0.061793
|
feed.49.ticker_sentiment.5.ticker
CMND
|
feed.49.ticker_sentiment.5.ticker_sentiment_score
-0.070057
|
feed.49.ticker_sentiment.5.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.5.relevance_score
0.087824
|
feed.49.ticker_sentiment.6.ticker
SEEL
|
feed.49.ticker_sentiment.6.relevance_score
0.087824
|
feed.49.ticker_sentiment.6.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.7.ticker
SILO
|
feed.49.ticker_sentiment.7.relevance_score
0.087824
|
feed.49.ticker_sentiment.6.ticker_sentiment_score
0.0
|
feed.49.ticker_sentiment.7.ticker_sentiment_label
Neutral
|
feed.49.ticker_sentiment.7.ticker_sentiment_score
0.0
